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CHAPTER 1: INTRODUCTION
1.1 Oral Microbiology Background
The oral microbiome is quite complex; from the extreme numbers of oral microbiota that
colonize the oral cavity, to the different combinations of groups of oral microbiota that colonize
specific areas and surfaces of the oral cavity. The NIH Human Microbiome Project (HMP) has
recently revealed that the oral microbiome, as compared to the gut or skin, has the largest core of
commonly shared microbes among unrelated individuals

1, 2

. More specific to the oral

microbiome than the HMP, the Human Oral Microbiome Database (HOMD) (www.homd.org)
was developed using a provisional taxonomic scheme for unmatched oral bacterial isolates and
phylotypes. A total of 36,043 16s rRNA gene oral clone sequences were analyzed to identify
additional taxa not included in the initial set up of the HOMD. The HOMD consists of 619 Oral
taxa with 6 major phyla (Firmicultes, Bacteroidetes, Proteobacteria, Actinobacteria,
Spirochaetes, and Fusobacteria) that make up 96% of the taxa among all oral bacteria 3.
There are many different groups of microbiota that dominate depending on their location
in the oral cavity, such as the hard palate, saliva, subgingival plaque or throat. These groups can
be found in Table 1 below. For instance, in the healthy oral cavity, saliva contained the major
core genera of Prevotella, Streptococcus, Veillonella, Pasteurellaceae, Fusobacterium,
Porphyromonas, Neisseria, and unclassified bacteria (Uncl) 2. The most abundant that dominated
nearly all oral mucosal sites was Streptococcus: Streptococcus oralis, Streptococcus mitis, and
Streptococcus peroris 4.

2

Table 1. The core bacterial taxa in the oral cavity from over 200 healthy individuals participating in
HMP
High abundance core
genera in >75%
Other major core genera in >80%
Minor core genera in
Sample type
samples at >10%
samples at >1% abundance
>50% samples
abundance
Atopobium, Uncl.
Buccal
Uncl. Pasteurellaceae (16, 19), Gemella
Streptococcus (2)
Prevotellaceae, Uncl.
mucosa
(11)
Bacilli, Catonella
Hard palate

Streptococcus (2, 6)

Uncl. Pasteurellaceae (16), Veillonella
(4), Prevotella (10), Uncl.
Mogibacterium Catonella
Lactobacillales (13), Gemella (11)

Streptococcus (2),
Keratinized
Uncl. Pasteurellaceae
gingiva
(19)

Uncl. Bacilli
Streptococcus (2, 6), Veillonella (4),
Prevotella (10), Fusobacterium (9),
Uncl. Pasteurellaceae (16)

Palatine
tonsils

Mogibacterium, Uncl.
Firmicutes

Prevotella (10), Streptococcus (2, 6),
Veillonella (4), Uncl. Pasteurellaceae Uncl. Actinomycetales,
(16), Fusobacterium (9), Porphyromonas Tannerella, Kingella
(7), Neisseria (−)

Saliva

Streptococcus (2), Fusobacterium (9),
Capnocytophaga (−), Prevotella (−),
Uncl. Firmicutes
Corynebacterium (−), Uncl.
Pasteurellaceae (−)
Streptococcus (2), Capnocytophaga (−),
Corynebacterium (15), Uncl.
Uncl. Betaproteobacteria
Pasteurellaceae (−), Uncl. Neisseriaceae
(21), Fusobacterium (9)

Subgingival
plaque

Supragingival
plaque

Veillonella (4), Prevotella (10), Uncl.
Pasteurellaceae (16), Actinomyces (−),
Fusobacterium (9), Uncl.
Lachnospiraceae (−)

Mogibacterium, Uncl.
Firmicutes

Throat

Streptococcus (2, 6)

Tongue
dorsum

Veillonella (4), Prevotella (10), Uncl.
Uncl. Actinomycetales,
Pasteurellaceae (16), Actinomyces (14),
Streptococcus (2, 6)
Uncl. Bacilli,
Fusobacterium (9), Uncl. Lactobacillales
Peptostreptococcus
(13), Neisseria (8)

HMP 2, 4. In the parentheses is the corresponding operational taxonomic unites in the genus or family.
Uncl is the abbreviation used for unclassified.

3
There are a large number of different species, both bacterial and fungal, found in the
healthy. A study done by Kumar et al. in 2005 found that phylotypes significantly associated
with healthy patients were: Veilonella, Campylobacter gracilis, Abiotrophia adiacens,
Eubacterium

saburreum,

Capnocytophaga

gingivalis,

Capylobacter

showae,

Streptococcus mutans,

Gemella,

Streptococus

Abiotrophia,

sanguis,

Rothia dentocariosa,

Eubacterium, and Selenomonas 5. In healthy individuals, 5 genera of fungi have been found.
They are consisted of Candida species, Cladosporium, Aureobasidium, Saccharomycetales, and
Aspergillus 6.
Many studies have shown that specific oral bacteria are associated with disease. The most
prevalent worldwide chronic infectious disease, dental caries, has been found to have changes in
the abundance of genera depending on the stage of the caries 7. Dental caries was previously
thought to be associated with Streptococcus mutans, however, molecular analysis has shown that
there is a predominance of Atopobium, Propionibacterium or Prevotella, with Streptococcus or
Actinomyces in carious dental lesions 8. Other genera found to be associated with dental caries
are Lactobacillus, Atopobium, Olsenella, Propionibacterium, Bifidobacterium, Dialister,
Sphingomonas and Parascardovia

9

. The “Red complex”, consisting of Porphyromonas

gingivalis, Tannerella forsythensis (formerly Bacteroides forsythus), and Treponema denticola,
have been found to be elevated in patients with chronic periodontitis

10 5

. Aggregatibacter

actinomycetemcomitans has also been found to be a periodontal pathogen

11

. Whereas,

Tannerella forsythia, Peptostreptococcus micros (Parvimonas micra), Fusobacterium nucleatum
subsp., Haemophilus paraphrophilus and Capnocytophaga sp. have been found to be associated

4
with gingivitis

12

. Taxa also found to be associated with gingivitis included Fusobacterium

nucleatum subsp. polymorphum, Lachnospiraceae [G-2] sp. HOT100, Lautropia sp. HOTA94,
and Prevotella oulorum, whilst Rothia dentocariosa was associated with periodontal health

13

.

Halitosis bacteria are Porphyromonas gingivalis, Fusobacterium nucleatum, Prevotella
intermedia and Solobacterium moorei

14

. Particular Candida species have been found to be

involved in oral mucosal disorders in patients with xerostomia, such as Candida albicans,
Candida glabrata, Canadida tropicalis, and Candida krusei 15.
The analysis of the association of specific or groups of microbes with oral disease and
health have been a great insight to causes and treatment. The methods of determining the
microbiota include culture, PCR or qPCR after microbial DNA extraction, DGGE and Next
Generation Sequencing

5, 16, 17

. The continuation of further microbial associations with oral

diseases and building of the HOMD through microbial DNA extraction, directly from saliva, and
sequencing needs to be done, especially those that have not been done already, such as
xerostomia.
1.2 Xerostomia
Approximately 5.5% to 46% of the population suffers from the burden of xerostomia

18

.

The prevalence and diagnosis of xerostomia and salivary gland hypofunction is very difficult to
determine with certainty owing to the limited number of epidemiological studies and differences
in how the two conditions have been defined. Xerostomia is the subjective feeling of dry mouth,
a symptom that may or may not be accompanied by hyposalivation, an objective decrease in
salivary flow. The stimulated salivary flow rate for healthy, non-hyposalivation averages 1.5–2.0

5
mL/min and the unstimulated salivary flow rate is approximately 0.3–0.4 mL/min

18, 19

. For

xerostomia, however, the individual has a stimulated flow rate below 0.5 mL/min, and an
unstimulated flow rate below 0.12-0.16 mL/min

20

. Chronic xerostomia has significant negative

implications that may affect the comfort of the oral cavity, bad oral hygiene and general wellbeing; salvia is very important for lubrication and oral health; negative oral health such as dental
caries, oral fungal infections, halitosis, or burning mouth

19-21

. The cause of xerostomia can be

induced from both salivary and non-salivary reasons (such as mouth breathing, psychological
disorders, and dehydration)

20

. There are several types of treatments and ways to manage the

negative side effects of the disease, however, further understanding at the microbial level may be
helpful in understanding the disease as a whole and may be helpful in developing better
treatments.
1.2.1 Causes
There are several possible causes for the development of xerostomia. The most frequent
cause of hyposalivation is the use of certain medications, radiotherapy to the head and neck, and
certain diseases. Other factors include salivary gland trauma or tumors, depression, anxiety and
stress, mouth breathing, psychological disorders, or malnutrition

18, 20

. Medications that have

been associated with dry mouth are anticoagulants, antidepressants, anti-hypertensives, antiretrovirals, hypoglycemics, levothyroxine, non-steroidal anti-inflammatory drugs, and steroid
inhalers

18

. Diseases that have been thought to cause xerostomia are Sjögren’s syndrome,

autoimmune disorders, diabetes mellitus, HIV, sarcoidosis, herpes virus, hepatitis C and endstage renal disease. Sjögren’s syndrome (SS), a chronic, autoimmune, inflammatory disorder

6
characterized by lymphocytic infiltration of the exocrine glands in multiple sites, most
commonly the lacrimal and salivary glands. It can occur alone (primary SS), or in conjunction
with another autoimmune rheumatic disease (secondary SS). Clinically, patients with SS most
often present with a complaint of dry eyes (keratoconjunctivitis sicca) and dry mouth 20.
1.2.2 Current Diagnosis Methods
The diagnosis of xerostomia is done through by assaying the individuals reported
symptoms, medication use, and past medical history. To help identify whether patients are
experiencing xerostomia or hyposalivation, several dental health questionnaires have been
proposed and used. These questionnaires ask questions about comfort of mouth, dryness of entire
internal and external oral cavity, if there is any difficulty talking, swallowing or eating dry foods,
and similar questions

18

. Medications that may reduce saliva flow should be noted when

identifying whether it could be a cause of the chronic xerostomia or hyposalivation. Finally, the
medical history should be examined for any radiation treatment of the head and neck region, and
other systemic diseases that have be found to induce xerostomia. In addition, an oral examination
can be used to identify clinical signs pathognomonic for hyposalivation. These signs include:
sticking of an intraoral mirror to the buccal mucosa or tongue, frothy saliva, no saliva pooling in
floor of mouth, loss of papillae of the tongue dorsum, altered/smooth gingival architecture,
glassy appearance to the oral mucosa (especially the palate), lobulated/deeply fissured tongue,
cervical caries (more than two teeth); and/or mucosal debris on palate (except under dentures) 22.
Another indication of xerostomia is found through a stimulated and unstimulated salivary flow
tests. Most of the tests are easy to perform and require little time. As previously mentioned,

7
xerostomia patients tend to have a stimulated flow rate below 0.5 mL/min, and an unstimulated
flow rate below 0.12-0.16 mL/min

20

. More extreme xerostomia diagnosis measures include

salivary imaging by ultrasonography or magnetic resonance imaging or salivary biopsy of the
major or minor salivary glands 20.
1.2.3 Current Treatment Methods
There are several treatment strategies that can be used for the management of xerostomia.
These strategies aim to reduce patients’ symptoms and/or increase salivary flow. Xerostomia
symptoms can be managed by diet modifications, proper hydration, increase in humidity at
night-time, avoidance of crunchy/hard foods and use of salivary substitutes and lubricants (such
as rinses, gels, sprays, toothpastes, and artificial saliva)

20

. Patients can increase salivary flow by

using sugar-free, xylitol-containing mints, candies and gum, sialagogues (drugs that increase
saliva flow) and acupuncture. Two systemic US Food and Drug Administration-approved
sialagogues are pilocarpine and cevimeline

18

. Following the bad oral hygiene that come from

xerostomia, individuals may have to treat these oral conditions by the restoration of dental caries,
antifungal medications to treat oral candidiasis, antibiotics for bacterial infections, and denture
adjustments and or denture adhesives 20. However, there are some preventative measures that can
be used to avoid some of the bad oral hygiene effects from xerostomia. By increasing the
frequency of oral/dental evaluation by a dentist and use of topical fluoride applications the status
of oral hygiene can be closely monitored and maintained 20.

8
1.2.4 Characterization of Xerostomia Microbiota
There is a great understanding of the implications of xerostomia, but there are few studies
that analyze the microbial environment by qPCR (quantitative polymerase chain reaction) or
NGS (next-generation sequencing), while others were done by culturing followed with qPCR for
identification. A recent culture study on xerostomia found total numbers of Candida albicans
were significantly higher in patients with xerostomia (67%) than in the controls (13%)

23

.

Irradiated, dentate, xerostomia individuals’ oral rinses were cultured and Acinetobacter,
Neisseria, Chryseomonas, Flavimonas, Pseudomonas, Citrobacter, Enterobacter, Escherichia,
Klebsiella, Flavobacterium and Weeksella species were prevelent

24

. Klebsiella pneumoniae

subsp. pneumoniae was found to be significantly more prevalent in the irradiated subjects, and
Enterobacteriaceae were found more frequently in aged irradiated subjects, where Citrobacter
freundii was also significantly elevated in the culture based study 24. Another culture study with
the addition of PCR identification showed mean levels of Streptococcus mutans, Lactobacilli
spp. and Candida spp. to be significantly higher in medicated hypertensive xerostomia patients
and primary Sjögren’s syndrome 17, 25.
Several studies that assay the microbial composition of dry mouth/hyposalivation. For
instance, a culture study done on complete denture wearers, found that as the salivary flow rate
(mL/5 min) decreased, it was found that the number of anaerobic bacteria and Candida species
increased 1.4 x 109 CFU/mL 26. Patients with Sjögren’s syndrome contained significantly higher
proportions of cultures of Streptococcus mutans, Candida albicans, Actinomyces naeslundii and
Lactobacillus spp. (specifically L. acidophilus)

27

. Head and neck radiotherapy patients’ saliva

9
was assayed by high-throughput sequencing, and 11 genera were found in all subjects:
Streptococcus,

Actinomyces,

Veillonella,

Capnocytophaga,

Derxia,

Neisseria,

Rothia,

Prevotella, Granulicatella, Luteococcus and Gemella 28.
Further research needs to be done with PCR and Next Generation Sequencing on DNA of
oral microbiota in xerostomia patients. Culture methods can be limiting in types of microbiota
growth and methods of non-specific oral microbial DNA extraction combined with PCR and
Next Generation Sequencing could be a better method for analysis. By getting a better, and full
understanding of xerostomia at the microbial level could help with better diagnosis and treatment
methods.
1.3 Standard Oral Hygiene Practices
Recent findings have found that douching is counterproductive in maintaining a healthy
collection of vaginal microbes

29

. With this idea in mind, are certain mouthwashes

counterproductive in keeping the healthy groups of oral microbes? The primary use for
antimicrobial mouthwashes is to reduce plaque and gingivitis. The American Dental Association
(ADA) puts an ADA-Accepted seal on antimicrobial mouthwashes that reduce plaque and
gingivitis better than brushing and flossing alone

30

. Mouthwashes can be composed of various

active ingredients that may or may not have antimicrobial agents. Available mouthwashes may
include the following active ingredients: antibiotics, bisbiguanide, chlorine derivatives, essential
oils, fluorides, oxygenating compounds, phenols, plant extracts, or quaternary ammonium
compounds

31

. Products that have earned the ADA Seal are those that contain 0.12%

chlorhexidine gluconate (CHG) or a fixed combination of essential oils (EO) such as Listerine®

10
30

. Several studies have been conducted on the effectiveness of different active ingredients on

oral health; however, there are few studies that actually characterize the changes of the oral
microbiota due to the main active ingredients in these products.
1.3.1 Effectiveness of Active Ingredients
When choosing a mouthwash or toothpaste to buy, the effect of it on its oral hygiene can
be a main deciding factor. Depending on its main active ingredients, it can act as an antiplaque,
antigingivitis, anticaries, desensitizing, or whitening agent. In order to know which mouthwashes
or toothpastes are any of these agents they must be tested. Mouthwashes including essential oils
have strong clinical evidence for efficacy against different oral biofilms bacteria

31, 32

have been shown to effectively act as both an antiplaque and anti-gingivitis agent

. They also
33

. Studies

testing various chlorhexidine varnishes as prevention for caries/biofilms were inconclusive; they
were effective against different oral biofilms, but, present a number of unwanted side effects and
should be prescribed with caution. It was recommended that further well-conducted randomized
trails be completed before being recommended for caries/biofilm prevention 31, 34. Mouthwashes
with 0.12% chlorhexidine or essential oils, and dentifrices containing triclosan with 2% Gantrez
copolymer

or

stannous

fluoride

reduce

gingivitis

33

.

Stannous

fluoride/sodium

hexametaphosphate provides antiplaque, antigingivitis, anticaries, and antisensitivity benefits 35.
The composition of oral microbiota can change based on the main active ingredients of
the mouthwash or toothpaste. These changes can possibly alter the composition of oral
microbiota, possibly eliminating both bad and good bacteria. What researchers need to determine
is what populations of oral microbiota flourish after use of these chemically different hygiene

11
applications. Several recent studies, mostly using culture techniques, have found reduction in
various select oral microbiota. For example, chitosan mouthwash interferes with the adherence of
all microorganisms in vitro
Streptococci mutans

37

36

. Xylitol in mouthwashes was found to reduce the number of

. The Green Tea Extract in mouthwashes was also found to decrease the

colony counts of Streptococci mutans and Lactobacilli
mouthwashes

reduce

plaque

accumulation,

gingival

38

. Cetylpyridinium chloride

inflammation and

also

Porphyromonas gingivalis and Fusobacterium nucleatum associated with halitosis

reduce
14, 39

.

Chlorhexidine (0.12%) has been found to reduce Aggregatibacter actinomycetemcomitans.
Escherichia coli and Streptococcus mutans counts were also reduced when a combination of
chlorhexidine gluconate and sodium fluoride were the main active ingredients in a mouthwash 11,
40

. Triclosan in toothpaste was found to significantly reduce the number of Candida albicans and

Streptococci mutans, however its efficacy as a mouthwash had limited data

40

. Antibacterial

toothpastes containing stannous fluoride were found to significantly reduce bacterial viability in
plaque left behind after brushing for up to 12 hours

41

. Biotene, a dry mouth wetting agent

containing lysozyme, lactoferrin, glucose oxidase, and lactoperoxidase, exhibited antimicrobial
activity against Streptococcus mutans and Lactobacillus acidophilus, but was not effective on
Candida albicans 42.
Analysis of previous studies provides some insight into which ingredients act as
preventative and whitening agents, and which species are decreased in numbers and counts. Most
of these studies only assayed specific species, so that alterations in the vast repertoire of other
species went unmeasured. Further research should examine the effects of the entire normal
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microbiota and determine which species colonize and flourish after a specific treatment. My
thesis research addresses this gap.
1.4 Specific Aims
The first specific aim was to design a human subject’s research proposal and
questionnaire that met Wayne State University (WSU) requirements. This research thesis
requires the participation of the WSU Institutional Review Board (IRB) committee, and
therefore, protocols, consent, and case report forms were developed for expedited approval. A
Dental Health Questionnaire (Appendix A) form was also approved and obtained for statistical
analysis. This specific aim was completed and accepted by the IRB committee (IRB protocol
number: 075914). The second specific aim was to optimize sample storage and DNA extraction.
Proper storage and DNA extraction of spit samples required the testing of several storage buffers
and lysis combinations. This aim was completed and a Saliva Storage Buffer (SSB) solution
combined with Fungal Lysis Buffer (FLB) confirmed no cell growth or DNA degradation. The
third and fourth specific aims include bacterial and fungal microbiome characterizations. Saliva
DNA samples from the xerostomia versus healthy study arm were completely characterized by
phylogenetic branch specific qPCR [24]. DNA from samples were stored for analysis by nextgeneration sequencing. Saliva DNA sample from the nightly oral hygiene practice study arm
were partially characterized. Fungal species in the xerostomia and healthy samples were
identified by qPCR and melt curve analysis, coupled with selective sequencing, as described
[25].

Statistical analysis to correlate compositions with patient data was performed with

GraphPad Prism 6 and other software, and with Microsoft Excel add-on tools.
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1.5 Significance
The primary purpose of this investigation is to define differences in oral microbiota
between healthy and xerostomia patients. We hypothesize that there will be differences between
the groups; if so, these differences will provide a basis for dealing with the problems associated
with xerostomia. A better understanding of the altered microbiota of xerostomia patients should
provide insights into more rational therapies. Also, characterization of combined bacterial and
fungal biomes is novel and may provide insight into oral candidiasis in these and in other groups
of patients. This will be done by microbial DNA extraction directly from saliva, using the mouth
as an incubator for normal microbial compositions per individual.
Secondary goals are to define day-to-day changes in oral microbiota in healthy
individuals, and to measure the impact of nightly oral hygiene practices on oral microbiota the
following day. We hypothesize that commercial mouthwashes/toothpastes alter the oral
microbiome in ways that may not foster the outgrowth of potentially beneficial species, based on
counter-productive use of douches in vaginal studies. A better understanding of the composition
of the oral microbiota as a whole, based on nightly oral hygiene practices, should provide
insights to which practice is most beneficial for fostering growth of beneficial oral microbiota.
These oral hygiene practices are done at night, before bed and without any food or water
between the nightly routine and the morning sample, to reduce the variables that change the oral
microbiota throughout the day. The mouth is then used as an over-night incubator for primary
colonies to become established based on their ability to flourish after the specific nightly oral
hygiene practice.
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CHAPTER 2: MATERIALS AND METHODS
2.1 Preliminary Trials & Saliva Storage/Lysis Buffers Methodology
2.1.1 Sample Collection Strategy
The xerostomia versus control study arm and the nightly oral hygiene study arm’s DNA
were collected the same way. To achieve extraction of DNA directly from saliva from all the oral
microbiota, a stable storage buffer combined with a productive DNA extraction method must be
carefully chosen. For the convenience of the volunteers and the number of daily samples needed
in the nightly oral hygiene study, saliva should be collected and stored until all samples are
completed and returned to the lab for DNA extraction. The saliva sample could possibly sit in the
buffer for at least 30 days. This buffer must not degrade cells and/or DNA from the saliva but
also should not promote new cell growth either. The buffer chosen must be stable across several
individuals, not inhibit or interfere with DNA extraction, and combined with the DNA extraction
method of choice, they must allow maximum DNA extraction across several oral species. The
storage buffer must also be non-toxic and chemically safe, in case small traces were to get on lips
during collection. However, volunteers will be strongly advised to not pour the buffer in their
mouths or consume it, no matter what buffer is chosen for the study.
To find this ideal storage buffer and lysis combination, several storage buffers/lysis
methods were tested from an aliquot of saliva from a single volunteer. Following the results of
this comparison, the 2 best storage buffers were tested with lysis across 4 different individuals.
Finally the best storage buffer was further tested on the prevention of cell growth and extraction
across several species.
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2.1.2 Initial Saliva Storage/DNA Extraction Testing
A single volunteer’s aliquot of saliva was tested across 7 storage buffers: Qiagen
RNAlater (Qiagen RNAlater RNA stabilization reagent, Qiagen Sciences, Maryland, USA), 91%
isopropyl alcohol (IPOH), 95% ethanol (EtOH), 1 x Fungal Lysis Buffer A (FLBA) (contents
listed in Appendix B) without potassium hydroxide (KOH), 1 x FLBA without KOH plus
ethylenediaminetetraacetic acid (EDTA), saliva with no buffer, and regular 1 x FLBA with
KOH, or a high SDS/alkaline lysis-phenol extraction 43.
To compare the longevity of bacterial DNA in saliva in the storage buffers, each was
tested at three time points: day 0 or same day processing, day 7, and day 30. Approximately 1.5
mL of each of the storage buffers was added to 500 µL aliquots of saliva. On the day of
processing, these were centrifuged at 16,060 x g, supernatants were discarded, and pellets were
suspended in 500 µL FLBA with 5 µL KOH (100:1). All of the storage buffers were then
incubated at 65°C for 2 hours and followed with centrifugation at 16,060 x g and collection of
the supernatant. Approximately 250 µL of Fungal Lysis Buffer B (FLBB) (contents listed in
Appendix B) was then added to the collected supernatant for neutralization (pH of approximately
7.8). Half of the FLB supernatant collected was placed in a new sterile 2 mL tube and purified
with buffer QG (Qiagen buffer QG buffer from Qiagen’s QIAquick Gel Extraction Kit, Qiagen
Sciences, Maryland, USA). Buffer QG was added to fill the 2 mL tube, then centrifuged 10 min
at 16,060 x g; the supernatant was bound to and washed with a Qiagen QIAquick spin column,
according to the manufacturer’s protocol. The column was then left to air dry for 10 minutes
followed by the addition of 200 µL of 1 x Tris-EDTA buffer (10 mM Tris pH 8.3, 1 mM EDTA;
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TE). After the TE was in the column for 5 minutes, the eluate was collected through
centrifugation at 16,060 x g and stored at -20°C until analysis. The remaining half of the
neutralized FLB supernatant was stored at -20°C until analysis.
An aliquot of purified DNA from each of the storage buffer variations with time periods
(total of 42 variations) was assayed by qPCR with a few primers: a 16s bacterial universal
primer, a primer to test for inhibition, and a phylogenetic branch-inclusive (PB) 16s
Lactobacillus primer. Lactobacillus was chosen since it is a gram positive bacterium, more
difficult to lyse and therefore a more stringent test of the buffers. Molecules per reaction or Cq
values were then compared for the top 2 storage buffers, those with best overall and best
Lactobacillus titers and with least inhibition; these were then tested on across a few different
individuals.
2.1.3 Secondary Saliva Storage/DNA Extraction Testing
After eliminating unacceptable saliva storage/DNA extraction methods from the initial
experiment, one buffer from the initial testing and two additional new buffers were tested on
their stability across multiple individuals. Four volunteers each provided an aliquot of saliva for
testing stability across 3 storage buffers: 91% IPOH, Saliva Storage Buffer (SSB; Appendix B)
and Qiagen’s buffer QG. Stability of DNA and extraction efficiencies were compared as
described above.
An aliquot of purified DNA from each of the storage buffer variations and time periods
from each individual (total of 20 variations) were assayed by qPCR with several primers: a 16s
bacterial universal primer, a primer to test for inhibition of the purified DNA in its buffer, and
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phylogenetic branch-inclusive (PB) 16s Lachnospiraceae primers

43

. Molecules per reaction

(calculated by CFX Manager™ Software v3.1) or Cq values were compared for the type of
storage buffer/processing method to use in both arms of the project.
2.1.4 Cell Viability Testing in SSB & IPOH
The viability of the saliva cells in the select buffers was tested to determine whether any
bacterial growth was occurring what might alter the initial populations, over a 28 day time
period. The buffers of choice, determined from the previous experiments, were IPOH and SSB
and the control buffer was 1x PBS (Appendix B). These three buffers were tested on two
different individuals’ saliva. For direct comparison of the three buffers across the 28 days a
single 36 ml aliquot of each buffer was compared for each subject. An aliquot of 4.5 ml of each
subject’s saliva was added to each of the buffer tubes. These tubes were then tested by CFU on
Trypticase Soy Agar (TSA; Appendix B). and aliquots were lysed with FLB for 8 different time
points (t = 0 [initial], 1 hour, 1 day, 5 days, 9 days, 13 days, 21 days, and 28 days) during the 28day testing. The initial time period (t = 0) is samples taken immediately after the saliva sample is
added to the buffer. These tubes were tested using two separate analyses. The first was cell
counting by streaking on select media. This experiment will show if there is any growth or death
of the saliva cells. The DNA was extracted (FLB method) from cells still alive in either the IPOH
or SSB buffer, amplified and sent out for sequencing. The second experiment requires extraction
of the saliva’s microbial DNA and qPCR to test for any changes in the species of the salvia
sample.
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When counting cells or colony-forming units (CFU), samples were serially diluted in
PBS (-1, -2, and -3) and 10 µL of each were spread uniformly with a sterile glass rod in a
quadrant on TSA. The plates were then incubated anaerobically in a candle jar at 37°C overnight
and colonies were counted in the quadrant that had the closest to 100 colonies, and calculations
were done to get the CFU/mL in each buffer at each time point. Pictures of each of the plates
were also taken. Cells still alive in either buffer were lysed using the FLB method described
previously in Section 2.1.1, except cells were scraped from agar using a sterile pipet tip and
mixed in the FLB solution. Then the DNA of these cells were amplified using qPCR with the
bacterial universal primer (16s) and prepped to be sent out for sequencing (method described in
Section 2.3.5).
During the DNA extraction portion, an aliquot of 4 mL was removed from the original
aliquot and centrifuged for 30 minutes at 16,060 x g. The buffer was then discarded and 500 μL
of FLB-A + KOH was added to the pellet, and processed using the FLB method (mentioned
above in section 2.1.2). Samples that originally contained SSB, however, did not need any FLBB because they were already neutral. To directly compare the three samples, each sample was
adjusted to a final volume of 850 μL with appropriate amounts of 1 x TE. Each of the samples
was then assayed by qPCR with two broad-spectrum bacterial primers: one spanning variable
domains 3-5 of the 16S ribosomal RNA gene, (Bu10) and the other spanning the internal
transcribed spacer between the 16S and 23S ribosomal RNA genes (BuITS). Melt peak results
were compared to monitor for overt changes in bacterial compositions.
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2.1.5 Species DNA Extraction with SSB/FLB Test
To determine if our extraction protocol and buffers compared well with commercial kits,
the chosen storage/lysis buffer (SSB/FLB) was tested against FastDNA™ KIT (MP
Biomedicals). The FastDNA™ Kit quickly and efficiently isolates high quality genomic DNA
from plants, animals, bacteria, yeast, algae, and fungi using Lysing Matrix A (garnet and one 1/4
inch ceramic bead) for cell lysis and a silica-based method for the purification process. To
compare these two extraction methods against each other, equal volumes of 10 different species’
DNA were extracted using both methods. The 10 species and collection methods are listed in
Table 5 in Section 3.1.4. Notably, we included several species of Streptococcus, which has a
reputation for poor extraction efficiency using commercial kits. The extracted DNA was
compared using the 16s bacterial universal primer and an inhibitory primer (DR3) in qPCR.
The 10 species were collected and grown by incubation for 48 hours in 37°C in a 2 mL
tube with 500 μL of LIB + supplements broth (Appendix B). A control tube was also made with
the same 500 μL aliquot that the other tubes received and also processed with both methods.
After incubation for 48 hours, an aliquot from each species tube adjusted to an optical density
(A600) and then at similar cellular densities species’ aliquots were individually prepped for
extraction. To do this, the cells were diluted 50-fold in new LIB media broth (196 μL of LIB
media and 4 μL of cells grown in LIB) and read in a Model 25 spectrophotometer (Beckman,
CA), blanking against LIB media only. Volumes were then adjusted, by adding small amounts of
LIB to get an A600 reading of 0.079 ± 0.0043.
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Samples were processed with the FastDNA™ Kit as outlined in its manual with the
modifications below. Aliquots of 100 μL of cells suspended in LIB (Appendix B) were
transferred into a new tube and centrifuged. The supernatants were discarded and 100 μL of
deionized water was added and the cells were re-suspended. This combination of cells and
deionized water were then moved into Lysing Matrix A tube. Then 1.0 mL of CLS-TC Cell
Lysis Solution was added to the Lysing Matrix A tube and was homogenized on a Krafttech™
(1/4 Sheet Palm Sander, PS160CA), because lack of FastPrep Instrument, for 40 seconds at 200
oscillations/second. Each tube was then centrifuged at 16,060 x g for 8 minutes to pellet debris
and the supernatant was transferred to a 2.0 mL micro-centrifuge tube. Equal volume of Binding
Matrix (1.0 mL) was then added to the tube and it was then incubated with gentle agitation for 5
minutes at room temperature on a rotator. After agitation the tube was centrifuged at 16,060 x g
for 10s to pellet the Binding Matrix and then the supernatant was discarded. In the next step, 500
μL of prepared SEWS-M was added and the pellet was re-suspended gently using the force of
the liquid from the pipet tip. This followed with centrifuging at 16,060 x g for 1 minute and
discarding supernatant, and then centrifuging at 16,060 x g for 10s and removing residual liquid
with a small pipet tip. The DNA was eluted by gently re-suspending Binding Matrix in 100 μl of
DES and incubating for 5 minutes at 55°C in water bath. The tube was then centrifuged at 16,060
x g for 1 minute. Finally, eluted DNA was transferred to a clean tube and appropriate amounts of
1 x TE was added to give a final volume of 800 μL and then stored at -70°C. The addition of TE
to get a final volume of 800 μL is done so that all samples have the same final volume.
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DNA extraction protocol via SSB/FLB: an aliquot of 100 μL of each of the species’ cells
grown in LIB were added to a 15 mL tube containing 2 mL of SSB and incubated at room
temperature for 1 week. After the cells sat in SSB for 1 week, the tube was then centrifuged at
16,060 x g for 15 minutes and the supernatant was discarded. The pellet was then left to air dry
in the tube for 10 minutes, and then processed with FLB (method described in section 2.1.2).
After being processed, TE was added to give a final volume of 800 μL and the sample was then
stored at -70°C.
2.2 Quality Control Methods
2.2.1 Saliva Storage Buffer Contaminants Methodology
The long-term storage of saliva in 4 mL of SSB buffer in the 15 mL tubes could
introduce contamination. To test whether this is an issue or not, 500 µL of SSB was evenly
distributed across the plate via a sterile glass rod, on two types of Agar: YPD+AMP and MLT
Max (both contents can be found in Appendix B). The aliquot of SSB came from the same lot
used for patient samples and was incubated for more than 30 days. A total of 6 plates were
tested, 3 of each type using 3 different tubes of SSB. The YPD + AMP plates were incubated at
room temperature and the MLT Max plates were incubated in candle jars at 37 oC for 5 days.
There was no growth on any of the plates.
2.2.2 DNA Extraction Contaminants Methodology
The process of extracting DNA from saliva that was stored in the SSB buffer for 30 days
could contaminate the samples. To demonstrate that contamination was unlikely, 12 mock
samples, leftover tubes of 4 mL of SSB that never received a saliva inoculum and held SSB from
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more than 30 days, were processed with FLB using the same process mentioned in section 2.1.2.
FLB samples were then tested at several dilutions in qPCR using the 3 universal primers and an
inhibitor testing primer.
2.2.3 Air Contaminants Methodology
The universal primers are very sensitive and could potentially detect air contaminants
introduced during the qPCR setup. Working in a lab where bacterial and fungal species are
constantly being streaked for growth, there can be a lot of airborne species, especially fungal and
mold. To test the possible air contaminants at my bench, 3 YPD +AMP Agar plates sat on with
lids off on my lab bench for several days. Only two colonies grew; DNA amplified from these
with FungalITS primers were sequenced to compare with targets derived from patient samples.
2.2.4 DNA Degradation Test
Each plate of samples endured multiple freeze-thaw cycles in order to complete different
primer qPCRs. This cycling could degrade the DNA templates. To test whether the DNA was
degraded, one of the master plates, XC1, was assayed with the same Bu10 primer after all of the
other primers were completed. Therefore, the initial Bu10 run molecules/reaction is directly
compared to the values obtained from a run at the end of the study.
2.3 Molecular Characterization Methods
2.3.1 Phylogenetic branch-inclusive qPCR Primers Construction
Bacterial and fungal compositions were initially analyzed by qPCR

43, 44 45

, using,

methods similar to those described by Lambert et al. for Phylogenetic branch-inclusive (PB)
qPCR

44

. Phylogenetic branch-inclusive (PB) qPCR uses PB primers that target a specific
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phylum or family or genus, making them far more inclusive than species-specific primers 44. The
collection was initially validated with target and non-target single species

43

. An aliquot of

purified DNA was assayed by qPCR with 3 universal (2 bacterial and 1 fungal) and phylogenetic
branch-inclusive (PB) primers and PCR conditions as described previously. Additional primers
used were Betaproteobacteria ITS in anticipation of oral Neisseria and Derxia, Streptococcus
ITS in anticipation of oral Streptococcus, Bacteroidetes ITS phylum primer in anticipation of
oral Capnocytophaga, Bacteroides, Flavobacteria and Prevotella, Actinobacteridae 16s in
anticipation of oral Actinomyces and Luteococcus, Megashaera 16s in anticipation of oral
Veillonella, Lactobacillaceae 16s and ITS in anticipation of oral Granulicatella, and
Enterococcaceae 16s in anticipation of oral Gemella. All primers with additional information
about each primer can be found in Appendix B.
Whether contaminants in a given sample inhibited or reduced the efficiency of qPCR was
determined by testing each with exogenous template and primers. We used an amplicon derived
from Deinococcus radiodurans, chosen because it amplifies with broad spectrum primers but not
with any PB primers, since it is a member of a distinct phyla (Deinococcus-Thermus). The
species are not normally found in the human body or our saliva samples 46. Inhibition of a DNA
sample in qPCR was determined using primer DR3 (Appendix D), specific for the
species Deinococcus radiodurans. In this inhibition testing qPCR, a fixed amount of amplicon
(7.5 ng/ 1 µL), made by ampifying D. radiodurans genomic DNA with DR3, was added to the
mastermix. This was distributed to all wells, except negative control wells. Standard wells
received no sample, only the amplicon mastermix. Samples were then added to all experimental
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wells. qPCR was performed with DR3. The distribution of Cq values of wells receiving both
sample and amplicon were compared to those with amplicon only. Wells whose Cq values were
more than 2 standard deviations from the average amplicon-only wells were considered to have
some level of inhibition, and would require retesting after further purification or after diluting
out contaminants causing the inhibition.
2.3.2 Biorad’s CFX Program-Cq Call Methods
The Biorad’s qPCR CFX program has three different methods for calling Cq values for
each qPCR run: Regression, Single Threshold-Auto, and Single Threshold-Custom. To
determine which method was the best for calling Cq values across multiple experiments, I
calculated the average and standard deviation of the Cq values from each dilution of the spike
amplicon, from 21 separate qPCR runs with Bu10, for each of the three methods. Then these
dilution averages were plotted against the log of its molecules/µL, giving the new averaged
standard slope per Cq call. The slope was then used to calculate the percent of efficiency for the
qPCR, %E = (10^ (-1 / slope) -1) * 100.
2.3.3 Determining Molecules/µL of DNA Methods
The Biorad’s CFX program allows the input of serially diluted standards (spike, usually
dilutions 10-4 to 10-9 containing 7.10 x 104 to 2.10 x 106 molecules/µL for each qPCR run. The
program then generates titers (molecules/reaction) for each sample individually derived from Cq
values. The percent compositions of target microbial groups for each sample can then be
calculated and compared between xerostomia and non-xerostomia groups using GraphPad
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Prism® 6 statistical software. I did not convert molecules per sample to cells per sample, because
the copy number of ribosomal RNA genes per genome varies from 1-15 depending on species 47.
The number of molecules/µL of the undiluted spike was calculated using by determining
the values of the mass of the spike in ng/µL and the length of the spike in bp, and converting
those values using the New England Biolabs Inc.’s dsDNA: Mass to Moles Convertor Calculator
(http://nebiocalculator.neb.com/#!/dsdnaamt). Once the molecules/µL of the spike was found, it
was easily converted into the correct dilutions used in qPCR (10 -4). The mass of the spike
(ng/µL) was determined using gel electrophoresis and a 100 bp ladder (GoldBIO.COM 100 bp
Plus TM DNA Ladder, CAT#D003-500). 10 µL of two-fold dilutions of amplicon was loaded
into 2 % Agarose LE Gel (contents can be found in Appendix B) and electrophoresed in 1 x SB
Buffer (contents in Appendix B) at 100 Volts for 45 minutes. The dilution of spike the intensity
of a similar size band of the ladder was used to approximate its mass in ng/5µL of spike.
2.3.4 Oral Bacterial and Fungal Library Construction
I assembled a repository of 364 live colony purified cultures from saliva of both healthy
and xerostomia volunteers, with matching DNA freezer stocks, listed in Appendix C. To start
this process, several 10 µL aliquots from both healthy and xerostomia saliva flow test tubes less
than 24 hours old, were streaked using the quadrant streaking technique on three types of Agar:
Human Blood Trypticase Soy Agar (TSA), Rogosa Agar, and MesLib (MLT) Agar (all agar
contents can be found in Appendix B). Plates were incubated anaerobically in 37 oC for 48 hours.
In the next step referred to as the “pie plates”, single isolated colonies were picked from the first
streaked plate onto a fresh agar plate of the same media, which is divided into several “pie
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slices”, one for each isolated colony, and picked colony is then re-streaked using the quadrant
form and incubated anaerobically in 37 oC for 48 hours. After cell growth, individual isolated cell
colonies were picked for making “nickels”; nickel-sized circles were drawn on the bottom of the
agar plates and each nickel is a different isolated colony. Rubbing the single isolated colony all
over the circle, overlapping parts of the circle multiple times, results are in confluent growth.
Plates were then incubated anaerobically in 37 oC for 48 hours. Once confluent nickels were
grown, FLB and Milk/Yeast Extract/Glycerol’s (MYEG) (Appendix B) were made. First using a
p10 pipette tip, a barely visible amount of the nickel is picked and put into 100 µL of FLBA and
KOH (100:1) in a 96 well plate, to make the FLB sample for qPCR. Then the rest of the nickel
was harvested and suspended in a 1.5 mL tube with 1 mL of MYEG mixture (Appendix B). The
nickel in the MYEG mixture is then mixed using the pipette and 100 µL aliquot is taken out and
put into the MYEG 96 well plate that matches the FLB plate. All nickels were photographed and
colony morphologies were recorded. Once all the nickels were made into FLB and MYEG
stocks, the MYEG plates and tubes were stored in a -70oC freezer. The FLB is processed as
described in Section 2.1.2. The finished FLB product is then stored in the freezer until qPCR
analysis. FLB’s of saliva cell colonies were diluted into 50 µL of 1 x TE using a pin replicator
(Scinomix, MO), which transfers ~0.5 to 1 µL, sterilized with a 5 min exposure to germicidal
ultraviolet light at a distance of 21 cm. These dilution master plates were then tested using 3
broad-spectrum primers (both bacterial universal primers and the fungal universal primer).
Samples from qPCR that had unique melting temperatures for combined bacterial universal
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primers were prepped and sent out for sequencing (method described in next section, Section
2.3.5).
2.3.5 Sequencing Methods
Two to three samples representing unique melt profiles across several experiments for
each primer were selected for sequencing. Samples were tested to see if they were positive and
composed of single discrete bands by gel electrophoresis: 10 µL of each post qPCR sample with
dye was loaded into individual wells of 2% Agarose LE Gel and ran in 1 x SB buffer at 100
Volts for 30 minutes. If samples showed no bands or multiple bands, they were not sent out for
sequencing. Samples with single discrete bands were enzymatically “cleaned” by the Exo-Sap
method

48

. Depending on band intensity, 3-5 µL of sample was adjusted to 5 µL with sterile

deionized water and added to 5 µL of the Exo-Sap. This was made for an entire 96 well plate as
follows: 2.4 µL of Shrimp Alkaline Phosphatase (SAP) (Tested User Friendly™, 1UN/µl, Lot:
114511), 24 µL Exonuclease 1 (Thermo Scientific, 20,000 U, Lot. 00132863), 48 µL of 10 x
PCR Buffer minus Mg (GIBCO-BRL, Lot No. 1090571), 192 µL of 25 mM MgCl2 (Promega,
Madison, WI, USA, A351B), 216 µL of Reverse Osmosis Water (ROW). Samples were
incubated at 37oC for 15 minutes, and then heat-inactivated at 65oC for 30 minutes. Primers were
then added (25 pmoles in 5 µL TE, adjusted with 25 mM MgCl2 to counter the EDTA in the TE
buffer. Samples were stored in a -70oC freezer until they were shipped to GenScript USA Inc. for
Sanger DNA sequencing 49 using “Big dye” chemistry 50, 51.
Sequences that were returned from GenScript were then matched using two online
microbial sequence databases: RDP Seqmatch (https://rdp.cme.msu.edu/seqmatch) and the NCBI
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BLAST® (http://blast.ncbi.nlm.nih.gov/Blast.cgi). For analysis of the 16S ribosomal RNA gene
amplicons, zipped folders containing the fas and ab1 files were uploaded into the RDP pipeline
for processing. Aligned sequences were seqmatched to the top 3 database entries (>1200,
Quality: Good). For the NCBI BLAST® sequence analysis, the “Nucleotide Blast” program was
used to find the species matches, testing several databases (nr), Whole-genome shotgun contigs
(WGS). For primers Bu10, EntC, Lachno2, LbITS, StaphITSO, and StrepITSO, the WGS
database was limited to Firmicutes. For primers Actino, BProITS, and OidesITS, the target was
limited to Actinobacteria, Proteobacteria, and Bacteroidetes, respectively. Once results were
given, samples matches with species that had a greater than or equal to 97% identity and query
coverage were accounted for within each primer set. For the remaining primer, Mega, amplicons
that were sent out for sequencing, the NCBI BLAST® was used for analysis of the sequenced
species. The “Nucleotide Blast” program was used to find the species matches. Once directed to
“Nucleotide Blast”, the database was “nr”, limited to Bacteria. Once results were given, samples
matches with species that had a greater than or equal to 97% identity and query coverage were
accounted for within each primer set.
The fungal ITS sequences were analyzed by aligning the reads using Mega 6 Muscle
Alignment. This identified poor base calls particularly at the ends. Ends were trimmed to
conservative shared calls; poorly aligning or short reads were discarded. Remaining sequences
were Megablasted at the NCBI website against both nr and WGS databases to identify closest
matches.
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2.4 Study Setups & Experimental Plans
2.4.1 Volunteer Enrollment
Xerostomia and healthy volunteers will be identified and enrolled with the help of a
participating dental office, and additional healthy volunteers will be self-enrolled by paper and
Internet postings on Wayne State University Pipeline. Nightly oral hygiene practice volunteers
were enrolled by paper and Internet postings on Wayne State University Pipeline. The
enrollment lasted approximately 35-45 minutes. During enrollment, volunteers were asked to
sign a consent form, fill out a dental health questionnaire (Appendix A) and perform a saliva pH
test and two five-minute Saliva flow tests (unstimulated and stimulated). Because a focus of this
project is xerostomia, we used stimulated and whole saliva (Saliva) as samples as our diagnostic
of xerostomia. In the pH Saliva test, volunteers stuck an end of short-range pH paper (Hydrion
Papers 4.5 to 7.5, Micro Essential Laboratory, N.Y.) in their mouth to get it moist and then
compare the color to the pH color standards. To perform the unstimulated saliva flow test,
volunteers were asked to try to not create any saliva flow and to drool into a 2.0 mL tube instead
of swallowing for duration of 5 minutes. To perform the stimulated saliva flow test, volunteers
were asked to chew on a 2” by 2” piece of sterile Parafilm® (Menasha, WI) and to saliva in a 15
mL tube instead of swallowing for a duration of 5 minutes. The unstimulated and stimulated
saliva flow tests were both recorded in mL/5 minutes.
2.4.2 Xerostomia vs. Control Study Arm Sampling Method
Volunteers were given instructions and materials to collect three Saliva samples on three
consecutive days at their homes, upon awakening and before eating, drinking, or brushing, to
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minimize those variables. Saliva is collected in a 15 mL sterile tube with Saliva Storage Buffer
(SSB), safe to participants. Saliva is stable to sit in buffer at room temperature for up to 30 days.
The inclusion criteria for xerostomia participants were as follows: 18 years or older, participants
must self-report subjective “dry-mouth” feeling over 3 months, and salivary flow test indicative
of hyposalivation: stimulated whole saliva flow rate below 0.5 mL/min
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. The inclusion criteria

for healthy control volunteers were: participants must not have self-reported subjective “drymouth” feeling in the previous 3 months or any of the following diseases: Patients with the
following diseases are excluded: Sjögren’s Syndrome, or enrollment visit symptoms of
xerostomia, head-and-neck radiation therapy, or trauma to salivary glands, and saliva flow tests
must report values denoting no xerostomia: Salivary flow test indicative of non-hyposalivation
(measurement of unstimulated whole saliva (UWS) above 0.12-0.16 mL/min and stimulated
whole saliva flow rate above 0.5 mL/min20. The exclusion criteria for both groups of the study
included the use of antibiotics 3 months prior to enrollment in the study.

2.4.3 Nightly Oral Hygiene Practices Arm Sampling Method
The exclusion criteria for volunteers of the study included the use of antibiotics 3 months
prior to enrollment in the study. Volunteers were given instructions (listed below) and materials
to collect 30 Saliva samples on at their homes. It is stressed that the participants do not eat, drink,
or brush after the specific nightly oral hygiene procedure is performed until the morning sample
is taken, upon awakening and before eating, drinking, or brushing, to minimize those variables.
The nightly variations in oral hygiene practices instructions:
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a. Days 1-5: no nightly mouthwash or brush, then morning 2 min brush with provided
Crest Pro-Health toothpaste and brush after sample collection.
b. Days 6-10: nightly mouthwash with 15- 20 mL Listerine Total Care Mouthwash
without brushing (for 60 seconds of vigorous swishing), then morning 2 min brush with
provided Crest Pro-Health toothpaste and brush after sample collection.
c. Days 11-15: nightly mouthwash with 15- 20 mL Crest 3D White Luxe Mouthwash
without brushing (for 60 seconds of vigorous swishing), then morning 2 min brush with
provided Crest Pro-Health toothpaste and brush after sample collection.
d. Days 16-20: nightly toothpaste with a 1-inch strip of Crest 3D White Toothpaste and
provided brush (brushing for 2 minutes), then morning 2 min brush with provided Crest
Pro-Health toothpaste and brush after sample collection.
e. Days 21-25: nightly toothpaste with a 1-inch strip of Colgate Optic White Toothpaste
and provided brush (brushing for 2 minutes), then morning 2 min brush with provided
Crest Pro-Health toothpaste and brush after sample collection.
f. Days 26-30: no nightly mouthwash or brush, then morning 2 min brush with provided
Crest Pro-Health toothpaste and brush after sample collection.
After the sample is taken, volunteers are asked to brush their teeth with the provided
toothpaste and toothbrush. Saliva is collected in a 15 mL sterile tube with Saliva Storage Buffer
(SSB), safe to participants. Saliva is stable to sit in buffer at room temperature for up to 30 days.
If participants forget on any given night to perform the indicated rinse, non-rinse, or brush, they
will simply skip sampling the next morning and resume the schedule the following night. They
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will perform the full 5 days of sampling, even if that requires 6 or more days because of skipped
days. If any product causes irritation, or any signs of oral infection or pain, participants will be
instructed to stop using it, and to see their dentists.
2.4.4 Sample DNA Extraction Method
After the Saliva samples sit in the SSB for at least 30 days the DNA is extracted. To
process the saliva samples and extract their bacterial and fungal DNA a Fungal Lysis Buffer
(FLB) was used. The samples are centrifuged and supernatant discarded. Pellet is suspended in
fungal lysis buffer A (FLBA) mixture with KOH, a high SDS/alkaline lysis-phenol extraction,
and then incubated at 65°C for 2 hours and followed with centrifugation at 16,060 x g and
collection of the supernatant. Addition of fungal lysis buffer B (FLBB) was not needed for
neutralization (pH of approximately 7.8), because it was already neutral. The samples were
stored at -20°C until assayed with qPCR.
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CHAPTER 3: RESULTS
3.1 SSB/FLB for Saliva Storage/Lysis Buffer
3.1.1 91% IPOH/FQ Prevailed in Initial Storage/Lysis Combinations
The 14 different saliva storage buffers/DNA extraction combinations (listed in Table 2)
were tested from a single volunteer’s aliquot of saliva, to compare the stability and longevity of
the saliva microbial DNA in each buffer by running a qPCR using a bacterial universal primer
(Bu10), a primer to test for inhibition (DR3), and a branch-inclusive 16s primer specific for
Lactobacillus species (LbITS). The goals for this experiment is to pick a combination or two that
show high titers (amount of DNA) for this individual tested for multiple time periods and the
sample must not be inhibited. Any samples that may show inhibition to samples or may be
negative at day 30 should not be considered for the study.
The total bacterial titers for each of the combinations, using a 16s bacterial universal
primer (Bu10), combined with the inhibitory primer data will help eliminate undesirable
storage/DNA lysis buffers. Table 2 presents the total bacterial titer, inhibitory values, and
Lactobacillus Cq values for the 14 combinations tested in the primary salivary storage/DNA
extraction buffer test on a single aliquot of saliva from one individual. The best dilution of the
combinations with the highest number of molecules/reaction was used compared for analysis.
There were 5 storage/extraction combinations that did amplify day 30 samples with the universal
primer: 91% IPOH/FLB, 95%EtOH/FLB, FLBA-KOH/FLB, FLBA+KOH/FLB, and RNAl/FQ.
From these, only FLBA+KOH/FLB showed large inhibition with a dCq value of 8.83, this
inhibition could have given a false negative. The combinations that had high bacterial titers and
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low inhibition (<2.00) at day 30 are: 91%IPOH/FQ (7.49 and 0.25, respectively), 95%EtOH/FQ
(7.05 and 1.23, respectively), RNAl/FLB (5.37 and 0.30, respectively), and Spit/FLB (7.92 and
1.97, respectively). Those combinations also gave desirable Cq values (<24) for Lactobacillus.
Overall from the 14 saliva storage/DNA extraction buffers tested, 91%IPOH/FQ showed the
lowest amount of inhibition, had a high return on bacterial molecules per reaction, and had a Cq
value <24 for Lactobacillus.
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Table 2. Total bacterial titers and inhibition values for day 30 of 14 storage/DNA lysis
combinations tested on a single individual’s saliva aliquot.
Bacterial 16s
Bacterial 16s
Lactobacillus
Inhibition
Universal
Universal
16s Primer
Primer
Dilution
Primer
Primer
Storage/Lysis
of Sample
Molecules/
Molecules/
Cq Value
dCq Value
Reaction
mL Saliva
1.31E+01
27.49
91%IPOH/FLB
10-1
3.9E+05
0.44
23.08
91%IPOH/FQ
undiluted
2.88E+07
4.6E+10
0.25
-1
1.31E+01
26.60
95%EtOH/FLB
10
3.9E+05
2.22
21.68
95%EtOH/FQ
undiluted
1.12E+07
1.8E+10
1.23
-1
1.31E+01
26.10
FLBA-KOH/FLB
10
3.9E+05
2.51
21.64
FLBA-KOH/FQ
undiluted
6.31E+05
1.0E+09
2.05
-1
19.86
FLBA+EDTA/FLB
10
7.19E+06
2.2E+11
2.25
19.39
FLBA+EDTA/FQ
undiluted
1.12E+06
1.8E+09
2.31
-1
1.31E+01
24.47
FLBA+KOH/FLB
10
3.9E+05
8.83
30.47
FLBA+KOH/FQ
undiluted
2.56E+06
4.1E+09
2.55
-1
22.62
RNAl/FLB
10
2.36E+05
7.1E+09
0.30
1.31E+01
18.90
RNAl/FQ
undiluted
2.1E+04
0.10
-1
22.81
Spit/FLB
10
8.34E+07
2.5E+12
1.97
20.06
Spit/FQ
undiluted
9.08E+06
1.5E+10
2.43
Values 1.31E+01 (molecules/reaction) and 3.9E+05 (molecules/mL saliva) were used for samples
that were below detection level in qPCR. The full names of the storage/lysis combinations are as
follows: 91% isopropyl alcohol with FLB lysis (91% IPOH/FLB), 91% isopropyl alcohol with FLB
lysis followed by QG prep (91% IPOH/FQ), 95% ethanol with FLB lysis (95% EtOH/FLB), 95%
ethanol with FLB lysis followed by QG prep (95% EtOH/FQ), 1 x Fungal Lysis Buffer A without
potassium hydroxide with FLB lysis (FLBA-KOH/FLB), 1 x Fungal Lysis Buffer A without
potassium hydroxide with FLB lysis followed by QG prep (FLBA-KOH/FQ), 1 x FLBA without
KOH plus ethylenediaminetetraacetic acid with FLB lysis (FLBA+EDTA/FLB), 1 x FLBA without
KOH plus ethylenediaminetetraacetic acid with FLB lysis followed by QG prep
(FLBA+EDTA/FQ), 1 x Fungal Lysis Buffer A with potassium hydroxide with FLB lysis
(FLBA+KOH/FLB), 1 x Fungal Lysis Buffer A with potassium hydroxide with FLB lysis followed
by QG prep (FLBA+KOH/FQ)Qiagen RNAlater RNA stabilization reagent with FLB lysis
(RNAl/FLB), Qiagen RNAlater RNA stabilization reagent with FLB lysis followed by QG
prep(RNAl/FQ), Saliva with no buffer with FLB lysis (saliva/FLB), and Saliva with no buffer with
FLB lysis followed by QG prep (saliva/FQ).
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3.1.2 Saliva Storage Buffer is Comparable to IPOH
The buffers 91%IPOH, Saliva Storage Buffer (SSB), and Qiagen’s buffer QG (QG),
combined with DNA extraction methods, were assayed amongst 4 individuals’ saliva samples by
using qPCR with a universal primer, inhibition testing primer, and a Lachnospiraceae species
primer. The goals for this experiment is to pick a combination or two that show high titers (amount of
DNA) for this individual tested for multiple time periods and the sample must not be inhibited. The

universal bacterial primer, Bu10, QPCR results from day 30 samples (Figure 1) suggests that
SSB combined with FLB is the best method, giving high average log titer values and the smallest
standard deviation from the 4 individuals 9.60 ± 0.59, respectively. The next best buffer/lysis
combination is 91% IPOH/FLB with average log titer values of 9.70 ± 0.73. SSB/FLB has a
standard

deviation

than

12

the

91%

IPOH/FLB

Figure 1. Bacterial titers of possible
storage/lysis buffers from day 30
samples. qPCR was ran using a 16s
universal bacterial primer, Bu10. An
aliquot of Saliva from 4 different
subjects sat in buffer for 30 days
before prepped for lysis.
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The day 30 buffer/lysis saliva samples were checked for inhibition by QPCR with primer
DR3 (Section 2.3.1; Appendix D). A table with the dCq values and average dCq values of each
buffer across individuals is located in Table 4. The total average dCq across all day 30 samples is
0.82 ± 0.52. All of the buffer/lysis preps, except QG, have average dCq values <1.0, indicating
that they were free of PCR inhibitors. A 1-way ANOVA Friedman test gave a P value of 0.0124
and the Dunn’s multiple comparisons test showed that QG was significantly different than the
standard.
Table 3. Levels of inhibition of qPCR of saliva DNA among five types of storage and extraction buffers.
IPOH/FLB
IPOH/FQ
SSB/FLB
SSB/FQ
QG
Volunteer 1
0.6
0.3
0.7
0.9
1.2
Volunteer 2
0.6
0.3
0.4
0.7
2.3
Volunteer 3
0.8
0
0.4
0.7
0.7
Volunteer 4
0
0.3
1.1
0.8
1.1
Average
0.50 ± 0.35
0.23 ± 0.15
0.65 ± 0.33
0.78 ± 0.10
1.33 ± 0.68
An aliquot of Saliva from 4 different subjects sat in buffer for 30 days before prepped for lysis. All
samples are a 10-1 dilution.

3.1.3 Both SSB & IPOH Prevent New Cell Growth
The two best saliva storage buffers (SSB and IPOH) and a control buffer, sterile saline
buffer (PBS), were tested for new cell growth (via colony forming-unit [CFU]) and by qPCR
analysis with bacterial universal primers for 8 time periods across 28 days. The percentage of
cells alive, Table 4, was calculated by counting the number of colonies in the quadrant that had
approximately 100 cells, times the dilution factor, times 100 to bring the 10 by amount of µL
plated to get the cells per mL still alive. Then the number of cells per mL still alive was divided
by the initial value of cells per mL alive and then multiplied by 100 to bring the 10 µL plated to
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Table 4. The percentage of cells alive in the potential saliva storage
buffers across 28 days.
Subject #1
Subject #2
Time in buffer
(days)
SSB IPOH
PBS
SSB IPOH
PBS
0
100
0
100
100
0
100
0.04
8
0
104
54
0
111
1
79
0
642
30
0
147
5
2
0
123
7
0
350
9
2
0
172
3
0
361
13
0.2
0
97
1
0
TNTC
21
0
0
5218
0
0
TNTC
28
0
0
TNTC
0
0
TNTC
Percentages were based off of the initial time (0) and were
calculated using the colony forming-units.

1 mL. IPOH immediately kills
all cells and prevents growth
from happening. In SSB cells
did not die immediately, but
in fact slowly die off. The
cells that remained alive in
SSB after several days were
processed,

amplified

with

qPCR using the bacterial universal primer (16s), sequenced, revealing that they were
Streptococcus salivarius and Staphylococcus aureus subsp. aureus.
Comparing the melt peaks from qPCR for each of the time points, listed previously, is a
good indication on whether the dominant species are changing over time. Both of the bacterial
universal primers were used. The 16s bacterial universal primer showed promising results for
both buffers tested. SSB, Figure 2 (A & B), had little to no variation in melt temperatures across
the days for both subjects. IPOH, Figure 2 (C & D), also had no variation between melt peaks for
both subjects tested.
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Figure 2. Bu10 melt curves for cells lysed from SSB and IPOH across 28 days. SSB
curves for Subject 1 and Subject 2 are A and B, respectively. IPOH curves for Subject 1
and Subject 2 are C and D, respectively. Bacterial universal primer Bu10 was used in this
qPCR. Each melt curve on the graph represents the aliquot taken and lysed at the specific
time period, the number corresponds to the time in days. The sample dilution used in this
qPCR reaction for SSB was 10-1 dilution and pin replication dilution for IPOH. Day 21
samples for both subjects from SSB and day 5 samples from Subject 2 from IPOH were
excluded from analysis due to contamination in its original sample.
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The melt curve results from the BuITS bacterial universal primer run determined which
storage buffer was going to be used in the study. Trial storage buffer SSB, shown in Figure 3,
gave very consistent melt peaks with Subject 1 (Figure 3A), providing evidence that there were
no changes in the dominant species across this samples time in the buffer. Subject 2, Figure 3B,
may look deceiving, however, all of the samples have two distinct matching melt peaks, showing
relative consistency. The average Cq values for each of the subjects are 21.7 ± 1.18 and 19.9 ±
1.00, respectively. These values are below 24, indicating that there were high titers of bacteria in
these samples. Unfortunately, IPOH melt peaks data was rejected because they failed for an
unknown reason; the DNA from the preps were previously shown to be good with the Bu10
primer.
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Figure 3. BuITS melt curves for cells lysed from SSB across 28 days for Subject 1 (A) and
Subject 2 (B). Bacterial universal primer BuITS was used in this qPCR. Each melt curve on the
graph represents the aliquot taken and lysed at the specific time period, the number corresponds
to the time in days. The sample dilution used in this qPCR reaction for SSB was 10-1 dilution
and pin replication dilution for IPOH. Day 21 samples for both subjects from SSB were
excluded from analysis due to contamination in its original sample. Curves from cells stored in
IPOH were rejected on the basis of qPCR quality, not a reflection of the storage.
3.1.4 Species DNA Extraction more efficient with SSB/FLB than commercial FastDNA™
Kit
SSB/FLB and FastDNA™ KIT extraction method extraction efficiency’s across 10
different species were compared using a spectrophotometer, and universal primers (Bu10 and
BuITS) and an inhibitory primer (DR3) in QPCR. The OD readings of the samples in the
spectrophotometer, shown in Table 6, were used to verify that the samples had approximately the
same number of cells. The OD readings combined had an average of 0.079 ± 0.0043, and only 3
samples (E.coli, L. crispatus, and L. gasseri) were outside the standard deviation (0.075 - 0.083).
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The samples were also tested for inhibition to make sure that this was not a problem in the
analysis. There was little to no inhibition in the species samples what were stored and extracted
with SSB/FLB. All were well below 0.15 except Lactobacillus jensenii, which is outside two
standard deviations (slightly inhibited). Lactobacillus jensenii is also outside two standard
deviation for FastDNA™ samples (slightly inhibited). The bacterial universal primer also
confirms that the Lactobacillus jensenii did show this slight inhibition of molecules.
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Table 5. Information about the 10 species compared in the extraction efficiency using
SSB/FLB and FastDNA™ Kit.
OD
Read

FastDNA
Molec/
mL

SSB/FLB
Molec/
mL

SSB/FLB:
FastDNA

0.087

6.0E+08

6.8E+09

11

0.079

3.4E+07

1.1E+09

32

0.074

1.8E+08

1.9E+09

11

0.084

1.8E+07

4.9E+09

272

0.078

5.6E+08

2.0E+09

4

frozen
cells

0.075

6.0E+06

1.9E+08

32

HM163**

frozen
cells

0.075

1.3E+06

2.2E+08

169

Streptococcus
downei

HM475**

frozen
cells

0.079

1.3E+06

1.3E+07

10

Streptococcus
mitis

HM262**

frozen
cells

0.076

6.0E+06

1.6E+09

267

Streptococcus
vestibularis

HM561**

Species

Strain

Escherichia
coli

XL1Blue*

Enterococcus
faecalis

RK22***

Lactobacillus
crispatus

HM370**

Lactobacillus
gasseri

HM642**

Lactobacillus
jensenii

HM646**

Streptococcus
agalactiae

31***

Streptococcus
cristatus

Stock
Origin
frozen
cells
freshly
grown
agar cells
freshly
grown
broth
cells
freshly
grown
broth
cells
freshly
grown
broth
cells

frozen
0.082
1.7E+04
1.7E+08
10000
cells
*Agilent Technologies, Inc (CA)
**BEI Resources, NIAID, NIH as part of the Human Microbiome Project (VA)
***Lab strain, identified by 16s Sequencing
Molecules/mL were calculated from the qPCR with the 16s bacterial universal primer Bu10
and dCq values were from qPCR with the inhibitor primer. 0.5 µL of undiluted FastDNA
and 10-1 diluted SSB/FLB samples were used for both primers.
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The qPCR using the universal primer Bu10 comparing the two methods, shown in Table
6 and presented in Figure 4, gave some interesting results. The SSB/FLB method was more
efficient at extracting amplifiable DNA than the FastDNA™ Kit. On average the SSB/FLB
method extracted 8.8 ± 0.8 molecules/mL sample (log) for the 10 species test, whereas
FastDNA™ only extracted 7.1 ± 1.4 molecules/mL sample (log). The FastDNA™ Kit results
support the theory that some commercial DNA extraction methods do not extract Streptococcus
species well, and in this case the small titer of S. vestibularis extracted was not recognizable by
qPCR. FastDNA™ is appropriate for extracting species other than Streptococcus, but SSB/FLB
is a better solution across all species tested and has 10-100 times more molecules of DNA from
most of the species tested.
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Figure 4. Comparison of FastDNA™ Kit to SSB/FLB across 10 species. (A) Ratio of
SSB/FLB to Fast DNA extraction methods. Data presented is from 16s bacterial universal
primer Bu10 qPCR using undiluted FastDNA™ and 10-1 diluted SSB/FLB samples. The
SSB/FLB samples molecules/reaction was converted to undiluted samples for comparison
against FastDNA™. (B) Log of molecules/reaction for species extracted using SSB/FLB. The
values used in this figure are the converted undiluted SSB/FLB Bu10 data.
3.1.5 Bu10 and BuITS Combined Give Unique Species Melt Temperatures
The bacterial universal primers melting temperatures can be used to decipher between
various bacterial species. Figure 5 is a digital representation of the melting temperatures of both
universal bacterial primers. Together they can help us distinguish between known species. There
is not enough variation between the Bu10 single melt temperatures. However, combined with the
multiple temperatures given from the BuITS primer it gives a unique fingerprint that reflects
dominant species in the sample.
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Figure 5. Composite melting
temperatures using Bu10 and
BuITS bacterial universal
primers. Species were
processed by the SSB/FLB
method. Bu10 is blue, and
BuITS is red.
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Using the known sequenced or BEI species’ melting temperatures, whether it is universal
or one of the branch inclusive primers, to help ID prevalent species in the saliva samples is one
of the key analysis methods. However, only the SSB/FLB identified species melting
temperatures can be used when identifying SSB/FLB saliva samples. This is because the melting
temperature is different between SSB/FLB and FLB only by an average standard deviation of ±
0.72 °C, seen Figure 6 (below). The FLB only cells were processed directly from frozen BEI
(BEI Resources, NIAID, NIH as part of the Human Microbiome Project [VA]) stocks into FLB.
The SSB/FLB samples were stored in SSB from frozen BEI stocks then processed with FLB
(detailed process was already mentioned). This large shift causes concern that species will not be
identified correctly, if any FLB only samples were used for standards. Therefore, only sequenced
or known samples that were processed with SSB/FLB will be used to identify the unknown melt
temperatures.

Figure 6. Changes in melting
temperatures of species that were
processed with FLB versus
SSB/FLB. Melting temperatures
are from a bacterial universal
Bu10 primer.
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3.2 Contamination control results
3.2.1 No Saliva Storage Buffer Contaminants
The distribution of 4 mL of SSB buffer into the 15 mL tubes for morning saliva samples
could induce contamination to the samples if not done properly. A total of 6 plates were tested, 3
of each type using 3 different tubes of SSB incubated for more than 30 days, from the same lot as
used for study patients. There was no growth on any of the plates.
3.2.2 No DNA Extraction Contaminants
The process of extracting DNA from saliva that was stored in the SSB buffer for 30 days
could have induced contamination to the samples. All samples showed no inhibition of a spiked
template, with an average of 0.09 ± 0.07 dCq relative to template alone. Two samples had
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positive melt peaks at 87°C with the bacterial 16s universal primer, however these samples had
very low titers of 19.3 and 14.7 molecules/reaction similar to those of the negative wells in the
qPCR. Also the duplicates of these samples did not show melt peaks and were also very low in
titer (1.50 and 4.37 molecules per reaction). Therefore, no high titer contaminants were present
to alter the titers of saliva samples.
3.2.3 Puccinia striiformis f. sp. tritici is an Air Contaminant
The universal primers are very sensitive and can amplify possible air contaminants.
Working in a lab where bacterial and fungal species are constantly being streaked for growth,
there can be a lot of airborne species, especially fungal and mold. Two colonies grew. FLB’s of
the colonies were made and tested with the fungal universal primer and were prepped to be sent
out for sequencing. The FLB’s of the two colonies had two identical melt peaks with averages
and standard deviations of 89.09 °C ± 0.07 °C and 85.36 °C ± 0.07 °C. Sequences came back as
Puccinia striiformis f. sp. tritici and none of the saliva samples tested have these melt
temperatures. Therefore it is unlikely that species detected in samples derive from the
environment in which the samples were processed.
3.2.4 DNA prepared by SSB/FLB DNA was not degraded during the study interval
Each plate of samples did endure multiple freeze thaws in order to complete different
primer qPCR’s. The concern is that these multiple freeze thaws would cause DNA template
degradation. I compared results from 108 samples assayed at the beginning of the study with the
same samples re-assayed 84 days later at the end of the study, after approximately 13 freezethaws (Figure 7). A Wilcoxon matched-pairs signed rank test had a P Value of 0.4298 and is
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considered not significantly different. Therefore, there was no significant DNA template/sample
degradation.
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Figure 7. Variation in molecules/reaction of first Bu10 qPCR run vs. last Bu10 qPCR run
for XC Study Arm. Molecules/reaction are the 16s bacterial universal Bu10 primer.

3.3 Molecular Characterization
3.3.1 qPCR Primers Biorad Cq Call Based on Highest %E
All three methods of calculating Cq values showed impressively low average standard
deviations among all serial dilutions (Figure 8). Therefore it is important to compare the percent
efficiencies to choose the best call. In this case with the Bu10 primer the Regression Cq call is
shown to be the highest, with an efficiency of 94.1%. Single Threshold-Custom and Single
Threshold-Auto follow with 82.8% and 82.7% respectively. For all other primers, the percent
efficiencies given by the CFX will be compared for each Cq call type for several runs and the
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highest % efficiencies will be used. Again, all of the primers used in this study can be found in
Appendix D, along with additional information regarding primer make-up and qPCR. The qPCR
run-to-run variation for each primer can be seen in the average and standard deviations of the
percent effiencies, Appendix D.
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R² = 0.9999
y = -3.473x + 36.3 E= 94.1%
R² = 0.9965
y = -3.8182x + 38.603 E= 82.8%
R² = 0.9999

Figure 8. The average standard slopes for each of the three methods of determining Cq
values in the CFX Biorad program. The Bu10 primer standard was compiled from 34 runs
and graph equations and percent efficiencies were calculated using excel; no outliers were
excluded.

3.3.2 Oral Bactria and Fungal Library Composition
All of the information on the 364 saliva cells species that were grown for the oral lab cell
library can be found in Appendix C. A total of 11 volunteers’ saliva was used to create this
library and 30.6% (110/364) of the oral cell library has been identified through sequencing. The
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library, chosen from different combined Bu10 and BuITS representative melting temperatures,
consists of 3 major phyla: Firmicute, Actinobacteria, and Proteobacteria. Figure 9 contains the
break-down of the contents of the oral library based on the sequencing results. 70% of the
species come from the families: Lactobacillaeae, Actinobacteridae, and Streptococcus. The oral
cell library consists of 230, or 63.2%, xerostomia saliva cells and 134, or 36.8%, healthy saliva
cells. From the identified saliva cultures, 51.8% were from xerostomia patients.
Species identified only found in these volunteers were (prevalence in parenthesis):
Lactobacillus fermentum (3), Rothia mucilaginosa (4), Staphylococcus epidermidis (3), and
Streptococcus salivarius (5). This data will be combined with all sequencing data and further
analyzed for differences among the groups in the next section, Section 3.3.3.
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Figure 9. Oral cultured library composition based on sequencing. (A) Phyla distribution of
oral cell library. (B) Family distribution of oral cell library. (C) Species of oral cell library
with prevalence, within 97 % identity over 97% read length. The different shades of colors
in the figures represent the phyla of microbes: green (Actinobacteria), red (Firmicutes), blue
(Proteobacteria), and black (other). All cells’ DNA sequenced were from 16s bacterial
universal primer qPCR.
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3.3.3 Composition of Sequenced qPCR Samples
A total of 401 DNAs amplified with a variety of primers (Table 6) were sequenced. Only
244 (60.8%) of the amplicons (from 12 primers) that returned readable sequences had species
matches with 95% coverage and identity. Any primers that did not return with sequences
matched with at least 95% coverage and identity and/or a majority of the amplified samples
matched species outside its target were rejected. Therefore, two primers were rejected,
ChlamITS (Chlamydia) and MycoUreaITS (Mycoplasmatales). All information on the amplicons
sequenced, including DNA sequence and melting temperatures, can be found in Appendix E. 157
(39.2%) were mixed template reads, which could be a result from codominant species. Overall,
49.2% of the sequenced amplicons were from the study salvia samples, 46.6% were from the
Oral Cell Library (Section 3.3.2), and the remaining 4.2% of the matched sequences came from
other previous experiments from Chapter 2, such as the air contamination experiment. The saliva
samples that matched species sequences came from 14 xerostomia volunteers, 15 control
volunteers, and 8 nightly routine volunteers.
A total of 68 species were identified across all the matched sequences. The distribution of
these species from each target primer is presented in Table 7 A & B. Only the Staphylococcus
primer amplified a sequence outside of its target branch; it had two reads with 99% coverage and
97-99% identities for Streptococcus pneumonia, likely resulting from the close relationship of
the two targets and the dominant titers of Streptococcus. The melting temperatures for each
species matched, listed in Appendix E, suggests what the dominant species of each sample is in
the study. However, it is important to note that the melting temperature for each species is primer
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specific. Further analysis on which species are more dominant in each saliva sample will be done
in Sections 3.4 and 3.5.
Table 6. Breakdown of sequenced matches

11

Total
Nontarget
0

Mixed
template
reads*
5

3

0

0

3

100

Bact-F

157

129

0

28

100

Ent-R

2

1

0

1

100

Primer Target

Primer

Primer
Name

Total
Samples

Total
Target

Actinobacteridae

ActinoR3

Actin-R

16

Betaproteobacteria

BProt16SITS

BPro-F

Percent
Target
100

Enterococcaceae

Bu4L
Bu4LC
Bu4L2
Bu4L3
EntcR

Fungal Broad-spectrum

RT2

Fung-R

74

49

0

25

100

Fusobacterium
Lachnospiraceae uc &
incertae sedis, Clostridium
IVa, Roseburia

Fuso-R6

Fuso-R

8

7

0

1

100

Lachno-R3

Lach-R

19

6

0

13

100

Lactobacillaceae

LB16SITSfvr
LB16SITSvsp
LB16SITSj
LB16SITSsc

Lacto-F

44

13

0

31

100

Megasphaera/Dialister/
Veillonella

MegaR869

Mega-R

4

4

0

0

100

Bacteroidaceae/ uc
Prevotellaceae

OidiesITSFa
OidiesITSFb
OidiesITSFc

Oides-F

16

9

0

7

100

Staphylococcus

Staph16sITS

Staph-R

44

14

2

30

88

Streptococcus

Strep16SITSL

Strep-R

12

1

0

11

100

Bacterial Broad-spectrum
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8
4
10
5
5
3
1

2
1
3
2
2
1

1

1
6
3
3
10
4
3
5
2
8
1
6

2

4
7
2
1
3
5
2
3
4
1
2
2

3
9

Total

Fung-R

Strep-R

Staph-R

Oides-F

Mega-R

Lacto-F

Lach-R

Fuso-R

Ent-R

Actin-R

Bacterial species detected
Actinomyces graevenitzii
Actinomyces odontolyticus
Actinomyces viscosus
Atopobium sp.
Rothia dentocariosa
Rothia mucilaginosa
Rothia sp.
Gordonia sp.
Gemella haemolysans
Gemella sanguinis
Gemella sp.
Fusobacterium nucleatum subsp.
Animalis
Fusobacterium
periodonticum
Oribacterium sinus
Stomatobaculum longum
Abiotrophia defectiva
Lactobacillus casei
Lactobacillus fermentum
Lactobacillus gasseri
Lactobacillus paracasei
Lactobacillus rhamnosus
Lactobacillus rossiae
Lactobacillus sp.
Veillonella dispar
Prevotella melaninogenica
Prevotella veroralis
Staphylococcus aureus
Staphylococcus epidermidis
Staphylococcus aureus subsp. Aureus
Staphylococcus caprae
Staphylococcus sp.
Neisseria flava
Neisseria perflava
Neisseria sp.
Neisseria subflava

Bact-F

A

Table 7 A. Sequence Read Summary
Target Primer Name

2
1
3
2
10
5
10
5
6
3
1
1
6
3
3
10
4
5
5
2
8
1
6
4
7
2
4
12
5
2
3
4
1
2
2
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Table 7 B. Sequence Read Summary

Aureobasidium proteae
Aureobasidium pullulans
Candida albicans
Candida dubliniensis
Candida glabrata
Candida parapsilosis
Candida tropicalis
Cladosporium perangustum
Cryptococcus sp.
Malassezia restricta
Metarhizium brunneum
Puccinia striiformis f. sp. Tritici
Rhodotorula mucilaginosa
Saccharomyces cerevisiae
Uncultured basidiomycete ITS region
Uncultured compost fungus 18S rRNA gene
Uncultured eukaryote clone
Uncultured fungus clone
Uncultured Glomus clone
Total

2
1
2
2
5
1
13
4
6
1
1
2
1
2
Fungal species detected

129

11

1

7

2
1
2
2
5
1
14
4
6
1
1
2
1
2

1

6

12

4

9

14

1

Total

Fung-R

Strep-R

Staph-R

Oides-F

Mega-R

Lach-R

Fuso-R

Ent-R

Actin-R

Bact-F

Bacterial species detected
Streptococcus pneumoniae
Streptococcus anginosus
Streptococcus australis
Streptococcus genomosp.
Streptococcus mitis
Streptococcus mutans
Streptococcus salivarius
Streptococcus salivarius subsp. Null
Streptococcus sp.
Streptococcus thermophilus
Haemophilus parainfluenzae
Haemophilus sp.
human oral bacterium
uncultured bacterium

Lacto-F

Target

B

1
1
17
2
1
2
1
1
1
4
1
3
1
1
4
1
1
6
1
50

1
1
17
2
1
2
1
1
1
4
1
3
1
1
4
1
1
6
1
244
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3.4 Xerostomia vs. Control Study Arm
3.4.1 Volunteer Enrollment
Each volunteer enrolled filled out a dental health questionnaire, the blank questionnaire can be
found in Appendix A, each enrolled volunteers answers are presented in Appendix F. A total of
Table 8. Characterization of xerostomia and control
volunteers
Xerostomia
Control
Enrolled
18
18
Male
4
10
Female
14
8
White
16
16
Black
1
1
Asian
1
1
Total

Average

36 volunteers were enrolled in this study,
18 xerostomia and 18 healthy controls. A
detailed

characterization

of

the

xerostomia and control volunteers is
found in Table 8.
Comparing the volunteer’s saliva

Diagnosed
xerostomia

4

0

Symptomatic
xerostomia

14

0

(control or xerostomia), can be seen in

Periodontal or
Gingivitis

3

2

Figure 10. There was no significant

Wear Dentures

2

3

difference

Cosmetic
Dentistry
Age (years)
Cavities (#)
Root canals (#)
Crowns (#)
pH

4
54.3 ± 22.9
10.3 ± 8.0
0.9 ± 1.3
2.7 ± 2.8
5.6 ± 0.5

1
55.7 ± 23.8
5.8 ± 5.5
0.8 ± 0.9
1.4 ± 2.4
5.9 ± 0.4

0.6 ± 0.4

1.4 ± 0.4

unstimulated and stimulated saliva flow

3.4 ± 1.7
4.0 ± 1.9

6.4 ± 2.5
7.9 ± 2.5

tests, both of their group means were

unstimulated
(mL)
stimulated
(mL)
flow sum (mL)

tests, in the groups that they enrolled as

between

controls

or

xerostomias’ saliva pH, due to definite
overlaps in these groups. However, even
though there are several overlaps also
seen

between

the

groups

in

their

significantly different. Mann Whitney t-
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tests gave a P value of <0.0001 for unstimulated and a P value 0.0002 for stimulated flow rates.
By combining the unstimulated value with the stimulated value the overlap between the two
groups was minimized but not eliminated, and their new means were significantly different with
a P value <0.0001 from a Mann Whitney t-test. However, because of the overlap between these
groups, one cannot use this test to solely determine whether they are xerostomic or not.

60

A

B
2.5

6.5

2.0

S a liv a F lo w (m L )

7.0

pH

6.0

5.5

5.0

4.5

1.0

0.5

0.0

C o n tr o l

X e r o s to m ic

C o n tr o l

X e r o s to m ic

D

C

14

10
8

***

6
4
2

S a liv a F lo w S u m ( m L )

12

S a liv a F lo w (m L )

****

1.5

12
10

****

8
6
4
2
0

0
C o n tr o l

X e r o s to m ic

C o n tr o l

X e r o s to m ic

Figure 10. Saliva tests’ results. (A) pH of enrolled control vs. xerostomia volunteers. (B)
Unstimulated saliva flow (mL) of enrolled control vs. xerostomia volunteers. (C) Stimulated
saliva flow (mL) of enrolled control vs. xerostomia volunteers. (D) Saliva flow sum of
enrolled control vs. xerostomia volunteers.
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3.4.2 Xerostomia patients’ saliva samples do not have higher bacterial loads than controls
The total bacterial titers (16s) for each volunteer varied up to 100 fold from one day to
the next, although the 3 sample limit did not allow a determination of whether these differences
were significant

(1-way ANOVA Dunn’s multiple comparisons test, P value >0.9). The

variations in the total fungi titers also failed the ANOVA test for significance. However, a 1-way
ANOVA test on the volunteer’s enrolled in the xerostomia vs. control study gave a P value of
<0.0001, indicating that the means vary significantly between individuals. Figure 11 A. presents
the total bacterial titers (16s) in log form for each individual’s three samples given. These titers
are at least partially confounded by variations in spit volumes, which ranged from 0.25 mL to 3
mL.
Individual differences in melting temperatures (dominant species) were found when
comparing samples from each individual sample, (Figure 11 B). This reflects daily changes in
which species are dominant. There is less deviation from day to day within individuals (average
standard deviation = 0.10 °C) than the deviation among all samples (standard deviation = 0.23
°C). These data also indicate that healthy oral samples almost always have several co-dominant
species, each contributing to the Tm values. Diagrams for each primer are found in Appendix F.
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Figure 11. Bacterial titers from xerostomia and control three sequential samples. Total titers
are found in (A) and melting temperatures can be found in (B). Data was generated from the
qPCR run using the bacterial universal primer (16s).
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3.4.3 Oral microbial composition for each volunteer
The composition of dominant species for each volunteer varies, but there are two phyla
that outnumber the others and compete for dominance: Streptococcus and Megasphera/
Dialister/ Veillonella (Fig. 12; Appendix L). The 2-way ANOVA test on the volunteer’s average
titers for each primer showed no significant difference of any individual compared to an overall
average titer per target, nor between average titers per target between control and xerostomic
groups. At the level of resolution depicted in Figure 12, there is not a dramatic difference in
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magnitudes of titer changes between controls versus xerostomic groups.

Volunteer ID

Figure 12. Percent composition of oral microbes for xerostomia and control volunteers. The
percentages are based on titers from each primer per individual. Each individuals’ three
samples were averaged.

64
3.4.4 Dominant populations of xerostomia and controls
Titer data was analyzed by using a Mann Whitney t-test on log molecules per reaction
values for each volunteer’s sample. Because there was no tight control of saliva volumes, I
compared titers of subgroups as percentages of total titers of the sample; the latter was
determined both by Bu10 titers and by summing titers from all PB qPCR reactions. Even with
overlap between the groups, there were significant decreases in a subset of bacterial branches’
average titers in xerostomia as compared to controls, most dramatically 5 and 18 fold reductions
in Lachnospiracea and in Bacteroidaceae, respectively (Fig. 13). Xerostomia samples were
significantly lower in microbial populations of Lactobacillaceae (1.3 x 104 in controls, 6.67 x
103 in xerostomia, P = 0.027), Betaproteobacteria (2.26 x 104 in controls, 8.18 x 103

in

xerostomia, P = 0.014), Megasphaera/Dialister/Veillonella (8.5 x 105 in controls, 4.82 x 105 in
xerostomia, P = 0.0068), Lachnospiraceae/ incertae sedis/ clostridum IVa/ Roseburia (1.75 x 103
in controls, 3.76 x 102 in xerostomia, P = 0.0003), and Bacteroidaceae/ uc Prevotellaceae (4.05
x 104 in controls, 2.31 x 103 in xerostomia, P = <0.0001). All of the figures for every primer of
control versus xerostomia can be found in figures in Appendix G.
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Figure 13. Average titers (log) significantly different for xerostomia and control volunteers.
The averages are based on titers from each primer per individual in each group. LBITS=
Lactobacillaceae, BProITS= Betaproteobacteria, Mega= Megasphaera/Dialister/Veillonella,
Lachno= Lachnospiraceae/incertae sedis/clostridum Iva/Roseburia, and OidesITS=
Bacteroidaceae/un Prevotellaceae
Xerostomia patient samples were depleted of several species relative to controls, as
indicated by missing or less prevalent species with BuITS or more specific primers (Figure #...).
Samples species were analyzed by uncorrected multiple comparisons Fisher’s LSD ordinary twoway ANOVA and significant species differences were seen in the several primers (Appendix H).
BuITS detected three species that were significantly lower in prevalence in xerostomia versus
control samples. They were BuITS-81.2 (10 in controls, 3 in xerostomia, P = 0.031), BuITS-85.6
(9 in controls, 2 in xerostomia, P = 0.031), and BuITS-88 (15 in controls, 5 in xerostomia, P =
0.0029). These species would reflect dominant bacterial species, either Streptococcus or
Megasphaera/Dialister/ Veillonella, therefore these could be: Streptococcus sp., Streptococcus
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mitis, Streptococcus salivarius subsp. Null, and Streptococcus mutans. Xerostomia also had a
significantly lower amount (17 in controls, 8 in xerostomia, P = 0.047) of Lachnospiraceae/
incertae sedis/ clostridum IVa/ Roseburia with the melt temperature of Lachno-86.4, based on
sequencing results this may be Oribacterium sinus.
Other branches that had a significantly lower prevalence in xerostomia were
Staphylococcus and Bacteroidaceae/ uc Prevotellaceae. Staphylococcus was also found to be
significantly lower (22 in controls, 14 in xerostomia, and 21 in controls, 11 in xerostomia, P =
0.020 and 0.0048) in species StaphITS-80.4 and StaphITS-80.6. Certain species of
Bacteroidaceae/ uc Prevotellaceae were found to be less prevalent in xerostomia. Xerostomia
had a significantly lower amount (15 in controls, 9 in xerostomia, P = 0.032) of OidesITS-81.6.
Bacteroidaceae/ uc Prevotellaceae also found to be significantly lower (8 in controls, 1 in
xerostomia, P = 0.013) in OidesITS-90, and sequencing results suggests this may be Prevotella
melaninogenica.
Some branches had a significant increase in prevalence for one species but a significant
decrease in another for xerostomia, based off of the control. For example, Lactobacillaceae
primers detected lower prevalence (16 in controls, 8 in xerostomia, P = 0.0043) of LBITS-87.6,
likely Lactobacillus fermentum, possibly Abiotrophia defectiva. In contrast there was higher
prevalence (2 in controls, 8 in xerostomia, P = 0.027) of LBITS-90.2. There was lower
prevalence of Betaproteobacteria among xerostomia patients (10 in controls, 1 in xerostomia, P
= 0.0038) of BProITS-86, but higher prevalence (3 in controls, 12 in xerostomia, P = 0.0038) of
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BProITS-84. These data indicate compositional changes in the two patient groups that warrant
further study by NGS.
Certain species of fungi were found to be more prevalent among xerostomia patients.
More prevalent species among xerostomia included Fungi-84.4 (6 in controls, 15 in xerostomia,
P = 0.029) likely to be Candida albicans, Fungi-84.8 (9 in controls, 23 in xerostomia, P =
0.0011) and Fungi-86.6 (18 in controls, 32 in xerostomia, P = 0.0011), likely Saccharomyces
cerevisiae and Candida albicans. In contrast, no melt/species of fungi was significantly more
prevalent in controls than in xerostomia. All of the significant differences in the species noted in
the paragraphs above are depicted Figure 14.
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Figure 14. Prevalence of species significantly different for xerostomia and control
volunteers. The averages are based on titers from each primer per individual in each group.
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3.4.5 Dominant populations of high flow versus low flow
Although significant differences
Table 9. Characterization of low flow and high flow sum
volunteers
Low Flow
High Flow
Enrolled
20
16
Male
5
9
Female
15
7
White
18
14
Black
1
1
Asian
1
1

Total

Diagnosed
xerostomia

3

1

Symptomatic
xerostomia

12

2

Periodontal or
Gingivitis

between xerostomia and controls were
seen for some bacterial groups, others
may have been overlooked due to the
imperfect grouping of the groups by
self-reported symptoms. Therefore all
volunteers were separated into two
groups based on their saliva flow sum
values to see if there were any

4

1

significant

Average

Wear Dentures

3

2

Cosmetic
Dentistry
Age (years)
Cavities (#)
Root canals (#)
Crowns (#)
pH

5
51.1 ± 24.1
9.3 ± 7.5
0.9 ± 1.3
2.3 ± 2.7
5.7 ± 0.5

0
59.8 ± 21.4
6.8 ± 6.6
0.8 ± 0.9
1.8 ± 2.6
5.8 ± 0.5

0.7 ± 0.5

1.4 ± 0.4

3.1 ± 1.2
3.9 ± 1.5

7.2 ± 2.0
8.6 ± 2.1

unstimulated
(mL)
stimulated
(mL)
flow sum (mL)

differences

between

microbial populations. Volunteers that
had a saliva flow sum <6.0 were put in
“low

flow”

(20

volunteers)

and

volunteers with a saliva flow sum of 6.0
or greater were grouped into “high
flow”

(16

volunteers),

based

on

observed gaps in the distribution. This

criteria moved three xerostomia individuals into the high flow group and five controls into the
low flow group. Table 9 gives a characterization of the two groups.
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Titer data was analyzed by using a Mann Whitney t-test. Low flow volunteers were
significantly lower in titer averages, as compared to high flow (control), most dramatically a 20
fold lower average titer for Bacteroidaceae/ uc Prevotellaceae (Figure 15). The following target
groups were lower: Betaproteobacteria (low flow 9.58 x 103, high flow 2.10 x 104, P = 0.0433),
Megasphaera/Dialister/Veillonella (low flow 4.80 x 105, high flow 9.20 x 105, P = 0.012),
Lachnospiraceae/ incertae sedis/ clostridum IVa/ Roseburia (low flow 4.36 x 102, high flow 1.76
x 103, P = 0.0053), Fusobacterium (low flow 2.32 x 104, high flow 6.85 x 104, P = 0.0047) and
Bacteroidaceae/ uc Prevotellaceae (low flow 2.30 x 103, high flow 5.83 x 104, P = 0.0003). All

Molecules/rxn (log)

of these differences in average titers per target can be found in figures in Appendix G.
7
6
5
4
3
2
1
0

Low Flow
High Flow

BProITS Mega

Lachno
Target

Fuso OidesITS

Figure 15. Average titers (log) significantly different for low flow and high flow
volunteers. The averages are based on titers from each primer per individual in each
group. BProITS= Betaproteobacteria, Mega= Megasphaera/Dialister/Veillonella,
Lachno= Lachnospiraceae/incertae sedis/clostridum Iva/Roseburia, Fuso=
Fusobacterium and OidesITS= Bacteroidaceae/un Prevotellaceae
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BuITS melt analysis of low versus high flow groups showed two species that differed in
prevalence. Melting temperature prevalence data was analyzed by multiple comparisons
uncorrected Fisher’s LSD ordinary two-way ANOVA and the significant species differences
were seen in the several primers (Appendix H). The first species BuITS-88 was found to be
significantly lower (low flow 2, high flow 18, P = 0.0022) in low saliva flow, but the second
species BuITS-88.4, was found to be significantly higher (low flow 23, high flow 9, P = 0.0066)
in low saliva flow. These temperatures would reflect dominant bacterial species, either
Streptococcus or Megasphaera/Dialister/ Veillonella, therefore these temperatures could be:
Streptococcus sp., Streptococcus salivarius subsp. Null, and Streptococcus mutans.
However, in the fungal universal primer ITS, all species were found to be significantly
higher in low flow. These are Fungi-84.4 (low flow 17, high flow 4, P = 0.0014; Candida
albicans, Candida tropicalis) Fungi-84.8 (low flow 22, high flow 10, P = 0.0029; Candida
albicans, Saccharomyces cerevisiae, Aureobasidium proteae), Fungi-86.4 (low flow 13, high
flow 5, P = 0.040; Candida albicans, or Uncultured basidiomycete), and Fungi-86.6 (low flow
29, high flow 21, P = 0.040; Candida albicans, Malassezia restricta). Another branch primers
that had species prevalence significantly higher in low flow was Lactobacillaceae.
Lactobacillaceae were found to be more prevalent at LBITS-87.8 (low flow 12, high flow 6, P =
0.035; Abiotrophia defectiva) and LBITS-90.2 (low flow 9, high flow 1, P = 0.0063).
Betaproteobacteria and Staphylococcus groups showed a significant increase in
prevalence for one species but a significant decrease in another for low flow compared to high
flow. Low saliva flow was found to have significantly higher in prevalence (low flow 16, high
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flow 5, P = 0.0024) of BProITS-83.6 for Betaproteobacteria, but significantly lower prevalence
(low flow 1, high flow 10, P = 0.011) in BProITS-86.0. Among Staphylococcus spp., low flow
was significantly lower (low flow 2, high flow 6, P = 0.039) in StaphITS-86.6 (Staphylococcus
epidermidis), but significantly higher (low flow 16, high flow 12, P = 0.039) in StaphITS-87.0
(Staphylococcus

aureus

or

Streptococcus

pneumonia).

Among

Bacteroidaceae/

uc

Prevotellaceae, species OidesITS-88.6 (Prevotella melaninogenica) was less prevalent in low
flow as compared to high flow (low flow 0, high flow 11, P = 0.0008). Figure 16 shows these
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significant differences between the species in these groups.

Figure 16. Prevalence of species significantly different for low flow and high flow
volunteers. The averages are based on titers from each primer per individual in each group.
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The analysis of low flow versus high flow groups was more sensitive for detected
differences in prevalence than was the xerostomic versus healthy grouping. Both showed
compositional differences that warrant further analysis by NGS.
3.4.6 Dominant populations of control versus medication
The volunteers of the xerostomia and control study were separated into two groups based
on their questionnaire answers
Table 10. Characterization of MIX vs. control volunteers
MIX
Control
Enrolled
11
11
Male
7
5
Female
4
6
White
10
10
Black
1
0
Asian
0
1

for medication to distinguish if
there

were

any significant

differences between microbial
populations. The first group
consisted of volunteers that

Total

Average

Diagnosed xerostomia

2

0

currently took medications that
Symptomatic xerostomia

6

0

Periodontal or
Givingivitis

0

1

and

Wear Dentures

1

2

“medication-induced

Cosmetic Dentistry
Age (years)
Cavities (#)
Root canals (#)
Crowns (#)
pH

2
57.1 ± 23.8
9.2 ± 7.1
0.9 ± 1.2
1.9 ± 2.0
5.5 ± 0.5

1
57.5 ± 24.7
6.4 ± 6.7
0.7 ± 0.8
1.8 ± 2.9
6.0 ± 0.4

xerostomia” or MIX group.

unstimulated (mL)
stimulated (mL)
flow sum (mL)

0.8 ± 0.5
4.2 ± 1.5
5.1 ± 1.8

1.6 ± 0.3
6.5 ± 2.5
8.0 ± 2.6

cause dry mouth and were

cause dry mouth (xerostomia)
were

named

the

The second group consisted of
age-matched volunteers that
did not take medications that

named

“controls”.
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Characterization of the volunteers in each of these groups can be found in Table 10.
Titer data was analyzed by using a Mann Whitney t-test. Significant decreases in titer
averages in MIX volunteers were seen in these three primers: Bacteroidaceae/ uc Prevotellaceae
(MIX 5.43 x 103, control 3.90 x 104, P = 0.0368), Betaproteobacteria (MIX 6.77 x 103, control
4.59 x 104, P = 0.0279), and Lachnospiraceae/ incertae sedis/ clostridum IVa/ Roseburia (MIX
5.68 x 102, control 2.21 x 103, P = 0.0159). These significant differences can be seen in Figure
17. All of the differences from each of the primers tested can be found in figures in Appendix G.

Molecules/rxn (log)
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Figure 17. Average titers (log) significantly different for xerostomia and control
volunteers. The averages are based on titers from each primer per individual in each
group. BProITS= Betaproteobacteria, Lachno= Lachnospiraceae/incertae
sedis/clostridum Iva/Roseburia, and OidesITS= Bacteroidaceae/un Prevotellaceae
There were several similarities and few significant differences between the prevalence of
the two groups’ species. Species prevalence data was analyzed by multiple comparisons
uncorrected Fisher’s LSD ordinary two-way ANOVA and the significant species differences
were seen in the several primers (Appendix H). The bacterial universal primer ITS, was shown to
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have three species that were significantly different between MIX and controls. The first two
species, BuITS-81.2 and BuITS-84.6, were found to be significantly higher (MIX 7, control 3,
and MIX 4, control 0, P = 0.042) in MIX, but the species BuITS-88, was found to be
significantly lower (medicated 4, control 9, P= 0.012). These temperatures reflect dominant
bacterial species in the Streptococcus or Megasphaera/Dialister/ Veillonella target group, likely
Streptococcus sp., Streptococcus salivarius subsp. Null, or Streptococcus mutans.
Branches that had a significant increase in prevalence for one temperature but a
significant decrease in another temperature for MIX, compared to controls, were found in the
fungal universal primer and Betaproteobacteria. Fungi species Fungi-84.6 (likely Cryptococcus
sp., possibly Candida albicans) were found to be significantly reduced in MIX (MIX 5, control
11, P= 0.048), but Fungi-86.4 (likely Candida albicans, possibly an uncultured basidiomycete)
were significantly increased in MIX (MIX 11, control 1, P= 0.0018). Betaproteobacteria species
BProTIS-84.0 were found to be significantly more prevalent (MIX 7, control 2, P= 0.013) in
MIX and species BProITS-85.6 and BProITS-86.0 were found to be significantly less prevalent
(MIX 0, control 4, and MIX 2, control 6, P= 0.043). Unfortunately, possible species for these
temperatures were not matched with DNA sequences from RDP for this primer.
Lactobacillaceae species were found to be more significantly prevalent in MIX
volunteers. LBITS-84.6 and LBITS-87.6 (Lactobacillus fermentum or Abiotrophia defectiva)
were found only in MIX (MIX 5, control 0, and MIX 11, control 6, P= 0.043). Species for these
temperatures did not closely match with DNA sequences from the RDP database for these
primers.
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Lastly, MIX volunteers were found to be significantly less prevalent in species from the
branches of Staphylococcus and Bacteroidaceae/ uc Prevotellaceae. Staphylococcus species of
StaphITS-80.8 (Staphylococcus epidermidis) were 10-fold more prevalent in controls (MIX 1,
control 9, P= 0.018). Bacteroidaceae/ uc Prevotellaceae species OidesITS-81.6 were 5-fold
more prevalent in controls (MIX 2, control 10, P= 0.0027) and OidesITS-90.0 was seen only in
controls (MIX 0, control 6, P= 0.021, respectively) in these volunteers.
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Figure 18. Prevalence of species significantly different for MIX and controls. The averages
are based on titers from each primer per individual in each group.
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3.5 Nightly Oral Hygiene Practices Arm
3.5.1 Volunteer Enrollment
Table 11. Characterization of nightly routine
volunteers
Enrolled
17
Male
8
Female
9
White
14
Black
0
Total
Asian
3
Periodontal or
Gingivitis
1
Wear Dentures
0
Cosmetic Dentistry
1
Age (years)
27.1 ± 10.5
Cavities (#)
4.5 ± 3.5
Root canals (#)
0.4 ± 1.0
Crowns (#)
0.2 ± 0.7
Average
pH
6.0 ± 0.5
unstimulated (mL)
1.0 ± 0.5
stimulated (mL)
6.3 ± 3.0
flow sum (mL)
7.3 ± 3.2

A total of 17 volunteers, 8 males and 9
females, were enrolled in this study with an
age range of 18-60 years, and an average age
of

27.1

±

10.5

years.

A

detailed

characterization of the xerostomia and control
volunteers is found in Table 11.
Titer data was analyzed by using a
1way ANOVA Dunn's multiple comparisons
test on log molecules per reaction values for
each volunteer’s sample per nightly routine
(Appendix J). Because there was no tight

control of saliva volumes, I compared titers of subgroups as percentages of total titers of the
sample. Even with overlap between the groups, there were significant decreases in many
bacterial branches’ average titers in different nightly routines as compared to no nightly oral
hygiene routine (none). Nightly oral hygiene routine samples were depleted of several species
relative to controls (none or no nightly routine), as indicated by missing or less prevalent melt
temperatures with BuITS or more specific primers (Appendix K). Samples melting
temperatures/species were analyzed by uncorrected multiple comparisons Fisher’s LSD ordinary
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two-way ANOVA and the significant species differences were seen in the several primers
(Appendix K).
Analysis in Section 3.5.2- 3.5.5 refer to titers averaged among the 17 patients.
3.5.2 Dominant species after Listerine mouthwash
After use of Listerine mouthwash (Fig. 19), Lactobacillaceae (1.03 x 104 in none, 4.17 x
103 in Listerine mouthwash, P = < 0.0001) and Fusobacterium (2.99 x 104 in none, 1.79 x 104 in
Listerine mouthwash, P = 0.01) titers were reduced about two-fold. Other average titers did not

Molecules/rxn (log)

show significant reduction.
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Figure 19. Average titers (log)
significantly different for
Listerine mouthwash and none
across all volunteers. The
averages are based on titers from
each primer per individual in each
group. LBITS= Lactobacillaceae,
and Fuso= Fusobacterium

None

LBITS
Fuso
Target
A number of specific species, as provisionally defined by their melt temperatures, were
reduced in prevalence after Listerine (Fig. 20). I use the nomenclature for these unnamed species
as follows: the primer being used – melt temperature. BuITS detected seven melt temperatures
that were significantly lower in Listerine mouthwash versus control samples: BuITS-80.4 (16 in
controls, 2 in Listerine mouthwash, P = 0.0168), BuITS-81 (15 in controls, 2 in Listerine
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mouthwash, P = 0.0299), BuITS-84.4 (20 in controls, 7 in Listerine mouthwash, P = 0.0299),
BuITS-86.4 (24 in controls, 11 in Listerine mouthwash, P = 0.0299), BuITS-88 (44 in controls,
29 in Listerine mouthwash, P = 0.0091), BuITS-88.2 (41 in controls, 17 in Listerine mouthwash,
P = < 0.0001), and BuITS-88.4 (37 in controls, 15 in Listerine mouthwash, P = < 0.0001).
Species Bu10-87.0 was more than two-fold less prevalent in Listerine mouthwash (58 in control,
25 in Listerine mouthwash, P = 0.059). Fusobacterium (Fuso- 85.0, possibly Fusobacterium
periodonticum) was also reduced in prevalence by at least two-fold (59 in controls, 25 after
Listerine mouthwash, P = 0.001). Fuso-85.2 (possibly Fusobacterium periodonticum) was
reduced by at least 1.6 fold with 59 in controls, 35 in Listerine mouthwash (P = 0.0229).
Lachnospiraceae/ incertae sedis/ clostridum IVa/ Roseburia detected species/melts that were
significantly lower than the control. The first, Lachno-86.4 (possibly Oribacterium sinus), was
two- to three-fold lower, 45 in none and 23 in Listerine mouthwash (P = 0.0152).
Lactobacillaceae detected three species/melts with significantly lower titers: LbITS-87.4,
possibly Abiotrophia defectiva (39 in controls, 21 after Listerine mouthwash, P = 0.0009),
LbITS-87.6 possibly Abiotrophia defectiva, 33 in controls, 21 in Listerine mouthwash (P =
0.0429), and LbITS-87.8 possibly Abiotrophia defectiva, with 41 in controls, 16 in Listerine
mouthwash (P = < 0.0001). One Lactobacillus species, LbITS-87.2, was 13-fold lower, but only
after Listerine mouthwash (13 in control, 1 in Listerine mouthwash, P = 0.0429). Strep-88 was
reduced more than two-fold (51 in controls, 18 after Listerine mouthwash, P = 0.0231).
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Figure 20. Prevalence of species significantly different for Listerine mouthwash and control
across volunteers.
3.5.3 Dominant species of Crest mouthwash
Bacterial populations were significantly decreased after nightly use of Crest mouthwash
in all six of the branches tested, by about 2 to 7 fold (Figure 21). This included: bacterial 16s
(1.30 x 106 in none, 4.47 x 105 in Crest mouthwash, P = 0.0006), bacterial ITS (6.35 x 105 in
none, 2.64 x 105 in Crest mouthwash, P = 0.0077), Lactobacillaceae (1.03 x 104 in none, 6.34 x
103 in Crest mouthwash, P = 0.023), Streptococcus (4.37 x 105 in none, 1.84 x 105 in Crest
mouthwash, P = 0.0445), Fusobacterium (2.99 x 104 in none, 1.07 x 104 in Crest mouthwash, P =
< 0.0001), and Lachnospiraceae/ incertae sedis/ clostridum IVa/ Roseburia (7.69 x 102 in none,
1.15 x 102 in Crest mouthwash, P = < 0.0001).
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Figure 21. Average titers (log) significantly different for Crest mouthwash
and none across all volunteers. The averages are based on titers from each
primer per individual in each group. Bu10= bacterial universal primer 16s,
BuITS= bacterial universal primer ITS, LBITS= Lactobacillaceae, StrepITS=
Streptococcus, Lachno= Lachnospiraceae/incertae sedis/clostridum
Iva/Roseburia, and Fuso= Fusobacterium

Crest mouthwash also reduced the prevalence of a number of specific species (Fig. 22).
BuITS detected six species/melts that were significantly lower in Crest mouthwash versus
control samples. They were BuITS-80.6 (22 in controls, 7 in Crest mouthwash, P = 0.0091),
BuITS-86.4 (24 in controls, 5 in Crest mouthwash, P = 0.0006), BuITS-87.8 (26 in controls, 11
in Crest mouthwash, P = 0.0091), BuITS-88 (44 in controls, 22 in Crest mouthwash, P = <
0.0001), BuITS-88.2 (41 in controls, 23 in Crest mouthwash, P = 0.0012), and BuITS-88.4 (37 in
controls, 14 in Crest mouthwash, P = < 0.0001). Species Bu10-87.0 was more than two-fold less
prevalent in Crest mouthwash (58 in none, 18 Crest mouthwash, P = 0.0019). Fusobacterium
(Fuso-85.0, possibly Fusobacterium periodonticum) was also reduced in prevalence by at least
two-fold (59 in controls, 26 after Crest mouthwash (P = 0.0014). Fuso-85.2 (possibly
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Fusobacterium periodonticum) was reduced by at least 1.6 fold with 59 in controls, 31 in Crest
mouthwash (P = 0.0069). Lachnospiraceae/ incertae sedis/ clostridum IVa/ Roseburia detected
species/melts that were significantly lower than the control. Lachno-86.4 (possibly Oribacterium
sinus), was two- to three-fold lower, 45 in none and 17 in Crest mouthwash (P = 0.0014).
Lactobacillaceae detected three species/melts with significantly lower titers: LbITS-87.4,
possibly Abiotrophia defectiva (39 in controls, 9 after Crest mouthwash (P = < 0.0001), LbITS87.6 possibly Abiotrophia defectiva, 33 in controls, 19 in Crest mouthwash (P = 0.0134), and
LbITS-87.8 possibly Abiotrophia defectiva, with 41 in controls, 20 in Crest mouthwash (P = <
0.0001).
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Figure 22. Prevalence of species significantly different for Crest mouthwash and control
across volunteers.
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3.5.4 Dominant species after Crest toothpaste
Crest toothpaste reduced average titers by a greater magnitude than the other routines, but
by at most 4-fold. Four bacterial populations were reduced after the use of Crest toothpaste (Fig.
23). This included: bacterial 16s (1.30 x 106 in none, 7.21 x 105 in Crest toothpaste, P = 0.0009),
Lactobacillaceae (1.03 x 104 in none, 4.05 x 103 in Crest toothpaste, P = < 0.0001),
Fusobacterium (2.99 x 104 in none, 1.64 x 104 in Crest toothpaste, P = 0.0069), and
Lachnospiraceae/ incertae sedis/ clostridum IVa/ Roseburia (7.69 x 102 in none, 3.53 x 102 in
Crest toothpaste, P = 0.0138).
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Figure 23. Average titers (log) significantly different for Crest toothpaste and none across all
volunteers. The averages are based on titers from each primer per individual in each group.
Bu10= bacterial universal primer 16s, LBITS= Lactobacillaceae, Lachno=
Lachnospiraceae/incertae sedis/clostridum Iva/Roseburia, and Fuso= Fusobacterium

Significant species were reduced in several targets (Fig. 24). BuITS detected five melt
temperatures that were significantly lower in Crest toothpaste versus control samples: BuITS84.6 (17 in controls, 2 in Crest toothpaste, P = 0.0091), BuITS-86.4 (24 in controls, 8 in Crest
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toothpaste, P = 0.0047), BuITS-88 (44 in controls, 21 in Crest toothpaste, P = < 0.0001), BuITS88.2 (41 in controls, 19 in Crest toothpaste, P = < 0.0001), and BuITS-88.4 (37 in controls, 11 in
Crest toothpaste, P = < 0.0001). Species Bu10-87.0 was more than two-fold less prevalent in
Crest toothpaste (58 in none, 20 in Crest toothpaste, P = 0.003). Fusobacterium (Fuso- 85.0,
possibly Fusobacterium periodonticum) was also reduced in prevalence by at least two-fold (59
in controls, 30 in Crest toothpaste (P = 0.0051). Fuso-85.2 (possibly Fusobacterium
periodonticum) was reduced by at least 1.6 fold with 59 in controls, 32 in Crest toothpaste (P =
0.0094). Lachnospiraceae/ incertae sedis/ clostridum IVa/ Roseburia detected species/melts that
were significantly lower than the control. The first, Lachno-86.4 (possibly Oribacterium sinus),
was two- to three-fold lower, 45 in none and 14 in Crest toothpaste (P = 0.0004).
Lactobacillaceae detected three species/melts with significantly lower titers: LbITS-87.4,
possibly Abiotrophia defectiva (39 in controls, 20 after Crest toothpaste (P= 0.0004), LbITS-87.6
possibly Abiotrophia defectiva, 33 in controls, 15 in Crest toothpaste (P= 0.0009), and LbITS87.8 possibly Abiotrophia defectiva, with 41 in controls, 14 in Crest toothpaste (P= < 0.0001).
Streptococcus detected two species/melts that were significantly lower in a few of the nightly
routines. Strep-87.6 was reduced ~2-fold (73 in controls, 36 after Crest mouthwash, P = 0.01,
and Strep-88 was reduced more than two-fold (51 in controls, 8 after Crest toothpaste, P =
0.0027).
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Figure 24. Prevalence of species significantly different for Crest toothpaste and control
across volunteers.
3.5.5 Dominant species of Colgate toothpaste
Overall, Colgate toothpaste only reduced average bacterial titers in Lactobacillaceae
(1.03 x 104 in none, 8.19 x 103 in Colgate toothpaste, P = 0.01; Fig. 25). Titers for each nightly
routine per branch tested, and all of the figures showing the effects of each nightly routine on
each volunteer per primer can be found in Appendix J.
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Figure 25. Average titers (log)
significantly different for
Colgate toothpaste and none
across all volunteers. The
averages are based on titers
from each primer per
individual in each group.
LBITS= Lactobacillaceae.
[Graph can be found in excel
file: “Thesis-ParagraphTables1”]

Significant species were reduced in prevalence, in several target groups (Fig. 26). BuITS
detected five species/melts that were significantly lower in Colgate toothpaste versus control
samples. They were BuITS-80.6 (22 in controls, 8 in Colgate toothpaste, P = 0.0168), BuITS86.4 (24 in controls, 9 in Colgate toothpaste, P = 0.0091), BuITS-88 (44 in controls, 23 in
Colgate toothpaste, P = 0.0001), BuITS-88.2 (41 in controls, 17 in Colgate toothpaste, P = <
0.0001), and BuITS-88.4 (37 in controls, 20 in Colgate toothpaste, P = 0.0024). Species Bu1087.0 was more than two-fold less prevalent in Colgate toothpaste (58 in controls, 29 in Colgate
toothpaste, P = 0.010). Fusobacterium (Fuso- 85.0, possibly Fusobacterium periodonticum) was
also reduced in prevalence by at least two-fold (59 in controls, 25 in Colgate toothpaste (P =
0.001). Fuso-85.2 (possibly Fusobacterium periodonticum) was reduced by at least 1.6 fold with
59 in controls, 36 in Colgate toothpaste (P = 0.0304). Lachnospiraceae/ incertae sedis/
clostridum IVa/ Roseburia detected species/melts that were significantly lower than the control.
The first, Lachno-86.4 (possibly Oribacterium sinus), was two- to three-fold lower, 45 in none
and 15 in Colgate toothpaste (P = 0.0006).

The second melt/species, Lachno-86.6, was
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significantly reduced only after Colgate toothpaste, by ~4-fold (38 in controls, 9 in Colgate
toothpaste, P = 0.0009). Lactobacillaceae detected three species/melts with significantly lower
titers: LbITS-87.4, possibly Abiotrophia defectiva (39 in controls, 20 after Colgate toothpaste (P
= 0.0004), LbITS-87.6 possibly Abiotrophia defectiva, 33 in controls, 15 in Colgate toothpaste
(P = 0.0009), and LbITS-87.8 possibly Abiotrophia defectiva, with 41 in controls, 17 in Colgate
toothpaste (P = < 0.0001). Streptococcus detected two species/melts that were significantly lower
in a few of the nightly routines. Strep-87.6 was reduced ~2-fold (73 in controls, 39 after Colgate
toothpaste, P = 0.0188). Strep-88 was reduced more than two-fold (51 in controls, 20 after
Colgate toothpaste, P = 0.0346).
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Figure 26. Prevalence of species significantly different for Colgate toothpaste and control
across volunteers.
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3.5.6 Fold titer decreases of differences in nightly routines
The above analyses focused on titers averaged over all patients to characterize trends that
might be expected in general. However, the strongest impacts depended on the individual and
were muddied by averaging. These widely varying reductions after nightly routines depend on
the individual, the target, and the treatment are detailed in Appendix L; representative examples
are shown in Figure 27. For example, five individuals show greater than 10 fold decreases
Lactobacillaceae after Listerine mouthwash use (Fig. 27A). The volunteers were M01 (↓15.8),
M06 (↓18.6), M10 (↓17.4), M13 (↓13.6) and M16 (↓10.5). Whereas, Lachnospiraceae/ incertae
sedis/ clostridum IVa/ Roseburia (Fig. 27B) had four individuals with greater than 10 fold
decreases after Crest mouthwash use, and of these four, three were different volunteers than seen
in Lactobacillaceae. The three that were greater than 10 fold were: M02 (↓10.2), M06 (↓43.7),
M11 (↓17782), M12 (↓55). M06 was seen to be reduced at least 15 fold with both nightly
routines and targets.
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Figure 27. Average fold decrease in titers. (A) Average fold decrease in titers in Listerine
mouthwash in Lactobacillaceae, (B) Average fold decrease in titers in Crest mouthwash in
Lachno= Lachnospiraceae/incertae sedis/clostridum Iva/Roseburia.

A more useful analysis of this information determined the number of volunteers with
greater than five-fold decreases in titer values (Fig. 28). Both Crest mouthwash and Crest
toothpaste significantly reduced the populations of Lachnospiraceae/incertae sedis/clostridum
Iva/Roseburia, in 5 individuals. Listerine mouthwash and Crest toothpaste decreased populations
of Lactobacillaceae also in 5 individuals. Overall, Colgate toothpaste had the least amount of
total patients with decreases greater than 5 fold in titers of targets. Whereas, Crest mouthwash
and Crest toothpaste tied with the greatest number of volunteers with decreases greater than five
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in target titers. With this knowledge at hand, it would seem that the most effective way to reduce
all of the target titers tested would be to combine the use of Crest mouthwash and Crest

# Patients with avg 5+ fold 
titer

toothpaste - where one fails, the other compensates.
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Figure 28. Prevalence of patients with 5+ average fold in titer difference. Fuso=
Fusobacterium, LBITS= Lactobacillaceae, Lachno= Lachnospiraceae/incertae
sedis/clostridum Iva/Roseburia, StrepITS= Streptococcus, and BuITS= bacterial universal
primer ITS.
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CHAPTER 4: CONCLUSIONS AND DISCUSSION
4.1. Overview
Most of the specific aims originally proposed for this thesis were accomplished. I secured
an IRB which allowed me to collect saliva samples and patient information from 18 controls and
18 patients who self-reported xerostomia. I also collected 30 samples from 17 control patients,
who practiced 5 different nightly oral hygiene routines before donating a saliva sample the next
morning. I developed a storage buffer that stabilized DNA in these samples for at least 30 days,
optimized a DNA extraction protocol and showed that it was more efficient at extracting
amplifiable genomic DNA across almost all tested bacterial species, including Streptococcus
species that are problematic with commercial extraction kits. I characterized and analyzed
microbial compositions of these samples using qPCR with broad-spectrum and phylogenetic
branch specific primers. I established a repository of 364 colony-purified oral bacterial species,
along with DNA preps of each, and verified 110 of these by sequencing.
4.2 Key findings
1. Microbial DNA can be effectively stored in SSB buffer for at least 30 days, and efficiently
extracted for qPCR with my modified FLB extraction protocol.
2. Oral bacterial species compositions identified by culture and qPCR were diverse and were
largely consistent with those characterized by NGS in the literature.
3. Oral bacterial compositions were dominated by Streptococcus species and those in the
Veillonella target groups, in both control and xerostomia groups.
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4. A core group of bacteria seen in all patients included Streptococus, Fungi, Fusobacterium,
Actinobacteria, Bacteriodaceae/ uc Prevotella and Veillonella. Groups that were seen more
sporadically included Lactobacilliaceae, Lachnospiraceae, and Betaproteobacteria. Patients
typically had at least 3 species at co-dominant titers, and these changed daily, often by an
order of magnitude.
5. Surprisingly, total bacterial titers and overall compositions at the branch levels were not
dramatically different in control versus xerostomia groups.
6. However, several subgroups of bacteria (Lachnospiraceae and Bacteroidaceae) were reduced
by 5 to 20 fold on average among xerostomic patients.
7. However, there were many bacterial and fungal species that were more prevalent in patients
with low saliva flow than those with high flow, and others bacterial species that were more
prevalent in high flow. These differences were enhanced by considering only patients whose
xerostomia was induced by medication.
8. Nightly oral routines did have an impact by reducing next-morning saliva bacterial
compositions and titers, but this was highly variable between individuals and routines.
Overall, Crest toothpaste and mouthwash routines reduced titers more in more individuals.
4.3 SSB/FLB as storage/lysis buffer
Microbial DNA can be effectively stored in SSB buffer for at least 30 days, and
efficiently extracted for qPCR with my modified FLB extraction protocol. With all of the
previous experiments on buffer/lysis saliva storage and extraction efficiency, it was in the
study’s best interest to use the saliva storage buffer SSB with lysis of FLB. The SSB has been
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optimized for the saliva samples in this study, finding that a 4.0 mL kills cells in the saliva and
prevents nucleic acid degradation for at least 30 days at room temperature. We also optimized
sample DNA extraction, finding that microbes pelleted from the storage solution, then subjected
to hot detergent–lysis, is as good or better across phyla than commercial DNA extraction kits.

4.4 Culture cell library
Oral bacterial species compositions identified by culture and qPCR were diverse and
were largely consistent with those characterized by NGS in the literature. Of my 110 sequenced
cultures I found 33 different species from 8 different Families. I was able to culture 3 of the 6
major phyla from HOMD (Firmicute, Actinobacteria, and Proteobacteria) 3. All of my cultures
were not identified by sequencing, because of lack of funds. Therefore, I cannot compare
distinctions between xerostomia individuals and control saliva cultures. Also, I did not culture
saliva on media that supported fungi growth and in-turn I cannot come to any conclusions on the
fungal populations in my culture library. However, my selective sequencing did identify species
consistent with the literature on oral microbiota, including: Lactobacilli spp.
Rothia, Gemella

17, 25

, Neisseria,
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, Streptococcus, Neisseria, and unclassified bacteria (Uncl) 2. This validates

the quality and analysis of my sequencing data. With further sequencing of the entirety of my
library, I am confident that we would be able to either confirm or refute the culture differences in
xerostomia or healthy individuals.
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4.5 Xerostomia vs. Control Arm
Saliva flow tests showed significant reductions in averages of unstimulated flow,
stimulated flow and saliva flows sum in self-reported xerostomia versus controls. However, there
was a great deal of overlap between these two groups. This could be due to poor categorization
based on ambiguous symptoms and self-reporting, in the first place. Individuals in the control
group that matched volumes of those in the self-reported xerostomia group could have never
noticed that they actually have low spit flow. In this case there could have been poor tools to put
each individual in each group. There was no significant difference in the pH of these two groups.
Surprisingly, bacterial titers and overall compositions at the branch levels were not
significantly different in control versus xerostomic groups. Oral bacterial compositions were
dominated by Streptococcus species and those in the Veillonella target groups, in both control
and xerostomia groups. These saliva compositions were also found to be part of the major core
genera in healthy oral saliva in literature 2. Literature also stated that Streptococcus was the most
abundant groups that dominated nearly all of the oral mucosal sites 4, this was also found true in
my volunteers’ saliva. Streptococus and Veillonella
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were also prevalent in Xerostomia

patients. A core group of bacteria seen in all patients included Streptococus, Fungi,
Fusobacterium, Actinobacteria, Bacteriodaceae/ uc Prevotella and Veillonella. Patients typically
had at least 3 species at co-dominant titers, and these changed daily.
Comparing target levels with-in the groups revealed that there was an 18 fold reduction in
Bacteroidaceae and a 5 fold reduction in Lachnospiraceae average titers in xerostomia. In fact,
all other significant differences between the two groups (less than 5 fold difference) showed a
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reduction in xerostomia. A logical explanation for this could be from the amount of saliva tested,
xerostomia patients could have had a harder time getting saliva into the test tubes causing this
“reduction” of cells. This also held true when comparing high flow to low flow and “medicationinduced xerostomia” (MIX) to controls.
However, there were many specific bacterial and fungal species that were more prevalent
in xerostomia patients than controls, and other bacterial species that were more prevalent in
controls. Xerostomia patients were found to have a higher prevalence in species OidesITS-81.6,
LBITS-90.2, BProITS-84, Fungi-84.4, Fungi-84.8, and Fungi-86.6. Some of these differences
were enhanced when comparing groups of low flow to high flow, such as Fungi-84.4, Fungi84.8, Fungi-86.6, LBITS-90.2. There were also higher prevalence seen when comparing MIX to
controls in: BuITS-81.2, Fungi-86.4, BProITS-84.0, and LBITS-87.6. BuITS-84.6, LBITS-84.6
were only seen in MIX. These species being higher in prevalence or found only in our dry mouth
patients could explain their negative oral hygiene. Fungi, for instance was found to be involved
with oral mucosal disorders

15

and Lactobacillus has been found to be associated with dental

caries 9. The species OidesITS-88.6 was non-existent in any of the low flow patients, and
BProITS-85.6 and OidesITS-90.0 were non-existent in the MIX patients. These species that are
lacking in the dry mouth patients could be the bacterial that is stabilizing the healthy oral
microbiome. Such as, Bacteriodetes have been abundant in healthy oral saliva 2. Identification of
these species through sequencing can give us a better understanding of their role.
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4.6 Nightly Oral Hygiene Practice Arm
Nightly oral routines did have an impact by reducing next-morning saliva bacterial
compositions and titers, but this was highly variable between individuals and routines. Average
titers across all individuals and Lactobacilli and Fusobacterium targets titers were significantly
reduced after Listerine mouthwash. Across all species showing differences, Listerine mouthwash
was found to reduce prevalence. All average target titers and species after nightly use of Crest
mouthwash was significantly reduced. The nightly use of Crest toothpaste showed 4-fold
decreases in average titers of bacteria 16s, Lactobacilli, Lachnospiraceae, and Fusobacterium, as
well as decreases in significant species. Colgate toothpaste resulted in significant decrease in
Lactobacilli and was also significantly reduced in several species prevalence. The use of these
nightly routines were found to significantly reduce average titers and certain species, as
expected.
However, individually volunteers had widely varying reductions in bacterial titer
populations following a specific nightly routine. In most cases only few volunteers had greater
than 5-fold decreases in bacterial titers after use of a nightly routine. Across all the targets tested
and nightly routines tested, there were only 6 instances in which Colgate toothpaste reduced
titers by more than 5-fold, only 11 times after Listerine mouthwash. Crest mouthwash and
toothpaste reduced titers more often, 14 occurrences each. Overall, Crest toothpaste and
mouthwash routines reduced titers more in more individuals. The groups affected most varied
between the two, suggesting that a combination of both treatments might be synergistic.
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4.7. Study Limitations
1. Only saliva samples were taken, restricted by feasibility, so bacterial compositions in other
oral niches, such as embedded in subgingival plaque, or tongue, were not collected and
therefore might be more of a factor in xerostomia or in assessing nightly routines.
2. Data from the xerostomia versus control patients’ needs more analysis at the individual level
to supplement my analysis of averaged data.
3. Amplicons that were identified by melting temperatures as being more prevalent in one
group or after a nightly routine, need to be identified to species by sequencing.
4. A number (155) of species that are potentially not in public databases were found by
sequencing but need further analysis to confirm whether they truly represent novel species.
5. Funding restricted use of NGS.
4.8. Future studies
In addition to conducting experiments to address the limitations listed in Section 4.7, if I had
another 6 months, these are the experiments I would pursue.
In the xerostomia arm, I would address the potential role of species that were more prevalent
in patients with low saliva flow. Since total bacterial loads were not dramatically different, the
poor oral hygiene status of the group (e.g. twice the incidence of cavities) may result from
virulence traits of these species, such as elaboration of metalloproteinases or enhanced biofilm.
Therefore, I would perform in vitro assays of relevant phenotypes, on pure cultures of species I
identified in this study to be more prevalent in xerostomic samples.

97
In the oral hygiene arm, I would pursue the observation that specific individuals show
much more dramatic reductions to a nightly oral routine than others. My hypothesis would be
that this variation results from specific differences in starting bacterial compositions, at the
species or even strain level. This effort would be enhanced by NGS analysis, which I could
perform on pooled and barcoded DNA samples in my repository. I would also test whether pure
cultures of species unique to high-responding patients were more sensitive to the mouthwashes
or toothpastes than their cousins from non-responding patients, with standard microbroth dilution
and viability assays.
The highly individualized responses shown after specific nightly hygiene practices
suggest that a large-scale prospective study is warranted. Participants’ responses to each routine
would be characterized as I did, and then they would be assigned their optimal hygiene regimen,
and tracked long-term with monthly sample monitoring. The issue I’d focus on, is whether
consistent reduction in one or more specific bacterial groups, which would differ in each cluster
of patients is strongly correlated with better oral hygiene. This I would quantify at the dentist,
with cavity and gum health assays. I’d also include a comparison group that was randomized
with respect to which nightly routine caused the largest reductions, to determine if
individualized, non-random routine groups had better oral health outcomes.
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APPENDIX A: QUESTIONNAIRE
Code ID:______ Date:_______
Dental health questionnaire
Age:_______ Sex:_______ Race:________ Ethnicity:__________
Have you read and signed the informed consent form for this study? YES ___ NO___
1. Are you currently in any pain? YES ___ NO___ Describe if yes_______________________________
2. Have you been hospitalized in the last two years? YES ___ NO___ Reason if
yes_________________________
3. Have you seen any physicians in the last two years? YES ___ NO___ Reason if
yes_______________________________
4. Have you been taking any medication in the past two years: YES ___ NO___ Describe if
yes_______________________
5. Are you allergic to anything? YES ___ NO___ Describe if yes_______________________________
6. Circle any condition you have had, or box if you currently have it:
AIDS/HIV
Asthma
Radiation treatment
Heart Disease/Failure
Liver Disease

Cold Sores
High blood pressure

Chemotherapy
Shortness of breath

Heart Attack
Hepatitis A, B, or C
Diabetes

Seasonal allergies
Epilepsy/seizures
Sinus problems

Kidney problems
Psychiatric care

7. How often do you brush? Once daily ____ Twice daily ____ Three times daily___ Other____
8. What brand of toothpaste do you currently use?______________________
9. Your brush is: Soft ___ Medium ___ Hard___
10. Your brush is: Manual____ Electric____ Brand_______________________
11. How often do you floss? Once daily ____ Twice daily ____ Three times daily___ Other____
12. How often do you use a fluoride mouthwash? Once daily ____ Twice daily ____ Three times
daily___ Other____ Brand________________
13. How often do you see your dentist? Once a year____ Twice a year____ Other_____
14. When you visit your dentist, do you most often have:
a. No new cavities___ b. One new cavity___
c. Two new cavities___ d. Other___
15. How many total cavities have you had filled? _____
16. How many root canals have you had?______
17. How many crowns have you had?______
18. Do you wear dentures? YES____NO____ If yes, for how long have you had
them?_________________
19. Have you ever been treated for periodontal/gum disease? YES ___ NO___ Most recent date:______
20. Have you had cosmetic dentistry, such as caps or veneers? YES____ NO____ List_______
21. Would you say your mouth is: comfortable?_____ moderately uncomfortable_____ very
uncomfortable____ if so, describe:____________________________________________
22. Do you have or have you ever had any of the following, if so, what was the most recent incident:
ms? YES ___ NO____ When?_____
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Sensitivity to sweets? YES ___ NO____ When?_____

YES ___ NO____ When?_____

h biting cheeks/lips? YES ___ NO____ When?_____
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APPENDIX B: MEDIA
Media
Type

Media Full Name

Ingredients

Blood TSA

Agar

Trypticase Soy Agar + human
blood

MLT Max

Agar

Mes-Lib-Thio-Casein-Starch

Rogosa Agar

Agar

Rogosa Agar

TSA

Agar

Trypticase Soy Agar

YPD + AMP

Agar

Yeast extract/ Peptone/
Dextrose Agar

LIB +
Supplements

Broth

Lactobacillus iners
Broth+Supplements (modified
from ATCC medium 1685
NYC III)

MYEG

Broth

Milk/Yeast Extract/Glycerol

30 g TSA powder, 15 g agar powder, 1 L
deionized water, 50 mL human blood
15 g Proteose Peptone No3, 4 g MES
powder, 5 g Glucose, 5 g yeast extract, 5 g
NaCl, 5 g Casein enzymatic hydrolysate, 1 g
starch, 0.5 g Cysteine HCL, 1.25 mL
Thioglycollate, 1 L deionized water
660 mL deionized water, 15 g Agar, 330 mL
Rogosa stock
30 g TSA powder, 15 g agar powder, 1 L
deionized water
10 g Peptone, 5 g yeast extract, 20 g
dextrose, 15 g Agar, 1 L deionized water,
1ml of a 10 mg/mL stock of Ampicillin
added after autoclaving
0.5 g/L cysteine, 4 g HEPES, 15 g Proteose
Peptone No.3 (BD 211693), 5 g NaCl, 875
mL deionized water, 5 g Glucose, 25 mL
Fresh Yeast Extract (Gibco 360-8180), 100
mL Heat inactivated horse serum
130 g dried milk, 5 g yeast extract, 10 g
dextrose, 1 L deionized water, autoclave and
cool to add 150 mL 100% sterile glycerol

FLBA

Buffer

Fungal Lysis Buffer-A

FLBB

Buffer

Fungal Lysis Buffer-B

1 x PBS

Buffer

1 x Phosphate Buffered Saline

8 mL deionized water, 2 mL 10%
TritonX114, 20 μL 0.5 M EDTA
2.5 mL 2 M Tris pH 8.3, 0.2 mL 0.5 M
EDTA, 0.41 mL conc. HCL, 22 mL
deionized water
8 g 137 mM NaCl, 0.2 g 2.7 mM KCl, 1.44
g 10 mM Na2PO4, 0.24 g 1.8 mM KH2PO4
(Cold Spring Harbor Laboratory Press, NY)

1 x Sodium Boric acid Buffer

~3700 ml deionized H2O (genetic), 100 mL
40 x SB, 80 uL Ethidium Bromide 52, Check
pH to be ~8.0, make as 40X stock

Saliva Storage Buffer
1 x TE

800 mL deionized water, 5.88 g sodium
citrate, 700 g ammonium sulfate, 40 mL 0.5
M EDTA, adjust pH to 5.2 with sulfuric acid
10 mM 83 Tris, 1 mM EDTA

Media Name

1 x SB Buffer

SSB
1 x TE

Buffer

Buffer
Buffer
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2% Agarose
LE Gel

Gel

2% Agarose LE Gel

250 mL deionized water, 5 g Agarose LE
Powder, 6.25 mL 40 x SB Buffer, 5 uL
Ethidium Bromide
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APPENDIX C: ORAL CELL LIBRARY
Table can be found in:
https://drive.google.com/drive/folders/0BwlH15OQpZ4kfjVPV3RxSzd4VkNJSDN1TnFVZjhFa
WY1d2pnUFdmdUd5czVTQ2g0XzVRaWs
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APPENDIX D: QPCR PRIMERS
Table can be found:
https://drive.google.com/drive/folders/0BwlH15OQpZ4kfjVPV3RxSzd4VkNJSDN1TnFVZjhFa
WY1d2pnUFdmdUd5czVTQ2g0XzVRaWs
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APPENDIX E: SEQUENCING MATCHES
Table can be found:
https://drive.google.com/drive/folders/0BwlH15OQpZ4kfjVPV3RxSzd4VkNJSDN1TnFVZjhFa
WY1d2pnUFdmdUd5czVTQ2g0XzVRaWs
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APPENDIX F: QUESTIONNAIRE FOR XEROSTOMIA AND CONTROL PATIENTS
Table can be found:
https://drive.google.com/drive/folders/0BwlH15OQpZ4kfjVPV3RxSzd4VkNJSDN1TnFVZjhFa
WY1d2pnUFdmdUd5czVTQ2g0XzVRaWs
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APPENDIX G: XC TITERS
Please see:
https://drive.google.com/drive/folders/0BwlH15OQpZ4kfjVPV3RxSzd4VkNJSDN1TnFVZjhFa
WY1d2pnUFdmdUd5czVTQ2g0XzVRaWs
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APPENDIX H: XC DOMINANT SPECIES
Please see:
https://drive.google.com/drive/folders/0BwlH15OQpZ4kfjVPV3RxSzd4VkNJSDN1TnFVZjhFa
WY1d2pnUFdmdUd5czVTQ2g0XzVRaWs
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APPENDIX I: QUESTIONNAIRE FOR NIGHTLY ROUTINE VOLUNTEERS
Please see:
https://drive.google.com/drive/folders/0BwlH15OQpZ4kfjVPV3RxSzd4VkNJSDN1TnFVZjhFa
WY1d2pnUFdmdUd5czVTQ2g0XzVRaWs
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APPENDIX J: NIGHTLY ORAL ROUTINE TITERS
Please see:
https://drive.google.com/drive/folders/0BwlH15OQpZ4kfjVPV3RxSzd4VkNJSDN1TnFVZjhFa
WY1d2pnUFdmdUd5czVTQ2g0XzVRaWs
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APPENDIX K: NIGHTLY ORAL ROUTINE DOMINANT SPECIES
Please see:
https://drive.google.com/drive/folders/0BwlH15OQpZ4kfjVPV3RxSzd4VkNJSDN1TnFVZjhFa
WY1d2pnUFdmdUd5czVTQ2g0XzVRaWs
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APPENDIX L: REDUCTION BY NIGHTLY ROUTINE PER INDIVIDUAL
Please see:
https://drive.google.com/drive/folders/0BwlH15OQpZ4kfjVPV3RxSzd4VkNJSDN1TnFVZjhFa
WY1d2pnUFdmdUd5czVTQ2g0XzVRaWs
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A thesis presented on the characterization of oral microbiota in xerostomic versus nonxerostomic volunteers and in daily samples following standard oral hygiene practices.
Xerostomia is a difficult and burdensome disease that can be very difficult to diagnose.
Understanding the oral microbiota between these diseased and healthy (non-xerostomic) can give
us great insight on new treatments and/or prevention. Goals of the study included determining
whether there substantial differences in oral microbial populations between the two groups, and
whether varying nightly oral hygiene practices had an impact on next-morning oral microbiota
titers or composition. Microbial loads were determined by qPCR using broad-spectrum primers.
Microbial compositions were estimated based on melt curve analysis of amplicons that spanned
the internal transcribed spacer between small and large ribosomal RNA genes, and by qPCR
using phylogenetic branch-specific primers. The project succeeded in developing and optimizing
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a storage media that allowed 30 day room temperature storage, and an DNA extraction method
that outperformed commercial kits.
The xerostomia versus control study used three sequential daily saliva samples, collected
from 18 xerostomia and from 18 healthy, control volunteers. Fungal populations and several
potentially novel species were found to be more significantly prevalent in xerostomia patients as
compared to healthy (P = 0.001). Surprisingly, total bacterial titers and overall compositions at
the branch levels were not dramatically different in control versus xerostomia groups. 6.
However, several subgroups of bacteria (Lachnospiraceae and Bacteroidaceae) were reduced by
5 to 20 fold on average, and specific species were less prevalent; among xerostomic patients, and
none were elevated. These studies suggest fungal species may play a role in the poorer oral
hygiene of xerostomic patients and that more detailed analysis using next generation sequencing
is warranted.
Mouthwashes and toothpastes are composed of several different ingredients, many of
which purported to have anti-caries or anti-gingivitis activities. However, the quantitative impact
of these is not well studied. The objective to this part of the thesis was to examine the shift in
populations after a specific oral hygiene practice repeated over 5 nights and assayed from saliva
the next mornings. This essentially uses the mouth as in incubator for microbial regrowth. A total
of 30 saliva samples were collected from 17 individuals the morning after a given nightly oral
hygiene practice, including no routine, Listerine mouthwash only, Crest mouthwash only, Crest
toothpaste only, and Colgate toothpaste only. These samples were analyzed using qPCR and
sequencing. Total bacterial loads returned to approximately the same levels after the 4 routines
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compared to no routine. Overall, Crest toothpaste and mouthwash routines reduced titers more in
more individuals. However, individual routines did have an impact by reducing next-morning
saliva bacterial compositions and titers of specific groups, but these reductions were highly
specific to the individual and the routine. This suggests that we have highly individualized
responses to common oral hygiene products, and that tailoring our choice of these to optimize
specific bacterial group reductions could improve oral health.
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